This application relates generally to the field of ophthalmic devices. More particularly, this application is directed to corneal masks and intraocular implants, and methods of making the same.
The human eye functions to provide vision by transmitting and focusing light through a clear outer portion called the cornea, and further refining the focus of the image onto a retina by way of a crystalline lens. The quality of the focused image depends on many factors including the size and shape of the eye, and the transparency of the cornea and the lens.
The optical power of the eye is determined by the optical power of the cornea and the crystalline lens. In a normal, healthy eye, sharp images of distant objects are formed on the retina (emmetropia). In many eyes, images of distant objects are either formed in front of the retina because the eye is abnormally long or the cornea is abnormally steep (myopia), or formed in back of the retina because the eye is abnormally short or the cornea is abnormally flat (hyperopia). The cornea also can be asymmetric or toric, resulting in an uncompensated cylindrical refractive error referred to as corneal astigmatism.
A normally functioning human eye is capable of selectively focusing on either near or far objects through a process known as accommodation. Accommodation is achieved by inducing deformation in a lens located inside the eye, which is referred to as the crystalline lens. Such deformation is induced by muscles called ciliary muscles. In most individuals, the ability to accommodate diminishes with age and these individuals cannot see up close without vision correction. If far vision also is deficient, such individuals are usually prescribed bifocal lenses.
For purposes of summarizing the disclosure, certain aspects, advantages and novel features of the invention have been described herein. It is to be understood that not necessarily all such advantages can be achieved in accordance with any particular embodiment of the inventions disclosed herein. Thus, the inventions disclosed herein can be embodied or carried out in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other advantages as can be taught or suggested herein.
A first aspect of this application is directed toward an ophthalmic device comprising a mask configured to transmit substantially all visible light along an optical axis of the eye, the mask further comprising a transition portion configured to switch between at least a first degree of opacity and a second degree of opacity; and wherein the transition portion comprises a photochromic chromophore within a polymer matrix.
The mask may include an aperture configured to transmit substantially all visible light along the optical axis of the eye.
The mask may include a plurality of holes extending at least partially between an anterior surface of the mask and a posterior surface of the mask.
An intraocular lens may be coupled with the mask.
The first degree of opacity may allow transmission of substantially all visible light through the transition portion of the mask.
The second degree of opacity may prevent transmission of substantially all visible light through the transition portion of the mask.
The transition portion of the mask may comprise at least 50% of the total mask.
The transition portion may be configured to switch between a first degree of opacity and a second degree of opacity via application of both light and heat.
The polymer matrix may have a glass transition temperature of between 30-150° C.
The photochromic chromophore may comprise spiropyran.
Another aspect of this application is directed toward a method of switching the opacity of at least a portion of an ophthalmic device. The method includes providing a photochromic polymer mask with a controlled glass transition temperature, inserting the mask into an eye, and applying light and heat to the mask.
The heat may be applied via a laser, via ultrasonic energy or other energy modality for elevating the temperature of the mask.
A microscope can be used to monitor the photochromic polymer mask.
The glass transition temperature may be controlled by altering the chain length of the polymer.
The glass transition temperature may be controlled by altering the cross-link density of the polymer.
Another aspect of this application is directed toward a method of forming a mask portion. The mask includes a transition portion configured to switch between a first degree of opacity and a second degree of opacity and an aperture in the mask portion, the aperture configured to transmit substantially all visible light along an optical axis of an eye.
The method may include forming a plurality of holes in the mask portion, the plurality of holes extending at least partially between an anterior surface and a posterior surface of the mask.
The method may include coupling the mask portion with an intraocular lens.
The transition portion may include a photochromic chromophore contained within a polymer matrix.
Various embodiments will be described hereinafter with reference to the accompanying drawings. These embodiments are illustrated and described by example only, and are not intended to limit the scope of the disclosure. In the drawings, similar elements have similar reference numerals.
This application is directed to ocular devices and implants (e.g., masks) for improving the depth of focus of an eye of a patient and methods and apparatuses for making such ocular devices. The masks generally employ small-aperture vision correction methods to enhance depth of focus in a presbyopic eye thereby providing functional near vision. The masks can be applied to the eye in any manner and in any anterior-posterior location along the optical path, e.g., as an implant in the cornea (sometimes referred to as a “corneal inlay”). The masks can also be embodied in or combined with lenses and applied in other regions of the eye, e.g., as or in combination with contact lenses or intraocular lenses (IOL).
The ocular devices and masks described herein can be applied to masks and/or combined with features described in U.S. Patent Publication No. 2011/0040376, filed Aug. 13, 2010, entitled “MASKED INTRAOCULAR IMPLANTS AND LENSES,” and International Patent Publication No. WO 2011/020074, filed Aug. 13, 2010, entitled “CORNEAL INLAY WITH NUTRIENT TRANSPORT STRUCTURES, hereby incorporated by reference in their entirety.”
A conventional intraocular lens 1000 is illustrated in
The intraocular lens and/or the lens body can be made from one or more materials. In certain embodiments, the intraocular lens and/or the lens body can comprise polymers (e.g. PMMA, PVDF, polypropylene, polycarbonate, PEEK, polyethylene, acrylic copolymers, polystyrene, PVC, polysulfone), hydrogels, and silicone).
A variety of variations of masks that can be used alone or positioned on or within the implant body are discussed herein, and also described in U.S. Pat. No. 7,628,810, U.S. Patent Publication No. 2006/0113054, and U.S. Patent Publication No. 2006/0265058, all of which are hereby incorporated by reference in their entirety.
The mask can have a constant thickness. However, in some embodiments, the thickness of the mask can vary between the inner periphery (near the aperture 2038a,b) and the outer periphery.
The mask can have dimensions configured to improve a patient's vision. For example, if the mask is embedded within the implant body, the thickness of the mask can vary depending on the location of the mask relative to the implant body. For example, the mask can have a thickness greater than zero and less than the thickness of the implant body. Alternatively, if the mask is coupled to a surface of the implant body, the mask can preferably have a thickness no greater than necessary to have desired opacity so that the mask does not add additional thickness to the intraocular lens. In certain embodiments, the mask has a thickness of greater than zero and less than about 0.5 mm. In some embodiments, the mask has a thickness of at least about 0.25 mm and/or less than or equal to about 0.3 mm. In some embodiments, the mask has a thickness of at least 0.005 mm and/or less than or equal to about 0.015 mm. In one embodiment, the mask has a thickness of about 0.25 mm. If the mask is on or near the surface of a transition zone, as described in U.S. Pub. No. 2011/0040376, filed Aug. 13, 2010 and hereby incorporated by reference in its entirety, the mask can have a shape similar or the same as the transition zone.
The annular region 2036a,b can be at least partially opaque or can be completely opaque to visible light. The degree of opacity of the annular region 2036a,b prevents at least some or substantially all light from being transmitted through the mask 2034a,b. Generally, transmission of light through the annular region will be no more than about 5%, often no more than about 3% and in some applications, no more than about 1%. Opacity of the annular region 2036a,b can be achieved in any of several different ways.
For example, in one embodiment, the material used to make mask 2034a,b can be naturally opaque. Alternatively, the material used to make the mask 2034a,b can be substantially clear, but treated with a dye or other pigmentation agent to render region 2036 substantially or completely opaque. In still another example, the surface of the mask 2034 can be treated physically or chemically (such as by etching) to alter the refractive and transmissive properties of the mask 2034a,b and make it less transmissive to light.
The material of the mask 2034a,b can be, for example, any of a variety of polymeric materials. Where the mask 2034a,b is applied to or fixed within the intraocular implant, the material of the mask 2034 should be biocompatible. Examples of suitable materials for the mask 2034a,b include the preferred PVDF, other suitable polymers or co-polymers, such as hydrogels, or fibrous materials, such as a Dacron mesh.
In additional embodiments, a photochromic material can be used as the mask or as a variable transmission zone in addition to a non-photochromic or non-variable transmission zone of the mask. Under bright light conditions, the photochromic material can darken thereby creating a mask (having a transmission aperture) and enhancing near vision. Under dim light conditions, the photochromic material lightens, which allows more light to pass through to the retina. In certain embodiments, under dim light conditions, the photochromic material lightens to expose an optic of the intraocular implant. Further photochromic material details are disclosed in U.S. patent application Ser. No. 13/691,625, filed Nov. 30, 2012, which is hereby incorporated by reference in its entirety.
The mask can have different degrees of opacity. For example, the mask can block substantially all of visible light or can block a portion of visible light. The opacity of the mask can also vary in different regions of the mask. In certain embodiments, the opacity of the outer edge and/or the inner edge of the mask is less than the central region of the mask. The opacity in different regions can transition abruptly or have a gradient transition. Additional examples of opacity transitions can be found in U.S. Pat. Nos. 5,662,706, 5,905,561 and 5,965,330, all of which are hereby incorporated by reference in their entirety.
Further mask details are disclosed in U.S. Pat. No. 4,976,732, issued Dec. 11, 1990, U.S. Pat. No. 7,628,810, issued Dec. 8, 2009, and in U.S. patent application Ser. No. 10/854,032, filed May 26, 2004, all of which are hereby incorporated by reference in their entirety.
An advantage to embodiments that include a mask with an aperture (e.g., pin-hole aperture) described herein over multifocal IOLs, contact lenses, or refractive treatments of the cornea is that all of these latter approaches divide the available light coming through the aperture into two or more foci while a mask approach has a single focus (monofocal). This limitation forces designers of multifocal optics to choose how much of the light is directed to each focal point, and to deal with the effects of the unfocused light that is always present in any image. In order to maximize acuity at the important distances of infinity (>6M) and 40 cm (normal reading distance), it is typical to provide little or no light focused at an intermediate distance, and as a result, visual acuity at these distances is poor. With a mask that includes an aperture to increase depth-of-focus, however, the intermediate vision of presbyopic patients is improved significantly. Indeed, the defocus blur with the aperture is less at intermediate distances than at near.
In one embodiment, the mask 2100 includes a body 2104 that has an anterior surface 2108 and a posterior surface 2112. The body 2104 can be formed of any suitable material, including at least one of an open cell foam material, an expanded solid material, and a substantially opaque material. In one embodiment, the material used to form the body 2104 has relatively high water content. In other embodiments, the materials that can be used to form the body 2104 include polymers (e.g. PMMA, PVDF, polypropylene, polycarbonate, PEEK, polyethylene, acrylic copolymers (e.g., hydrophobic or hydrophilic), polystyrene, PVC, polysulfone), hydrogels, silicone, metals, metal alloys, or carbon (e.g., graphene, pure carbon).
In one embodiment, the mask 2100 includes a hole arrangement 2116. The hole arrangement 2116 can comprise a plurality of holes 2120. The holes 2120 are shown on only a portion of the mask 2100, but the holes 2120 preferably are located throughout the body 2104 in one embodiment. The mask 2100 has an outer periphery 2124 that defines an outer edge of the body 2104. In some embodiments, the mask 2100 includes an aperture 2128 at least partially surrounded by the outer periphery 2124 and a non-transmissive or reduced transmissive portion 2132 located between the outer periphery 2124 and the aperture 2128.
Preferably the mask 2100 is symmetrical, e.g., rotationally symmetrical about a mask axis 2136. In one embodiment, the outer periphery 2124 of the mask 2100 is circular. The mask in general has an outer diameter of at least about 3 mm and/or less than about 6 mm. In some embodiments, the mask is circular and has a diameter of at least about 3 mm and/or less than or equal to about 4 mm. In some embodiments, the mask 2100 is circular and has a diameter of about 3.2 mm. In some embodiments, masks that are asymmetrical or that are not symmetrical about a mask axis provide benefits, such as enabling a mask to be located or maintained in a selected position with respect to the anatomy of the eye.
The body 2104 of the mask 2100 can be configured to be coupled with a particular intraocular lens design, either of reduced thickness design or of conventional design. For example, where the mask 2100 is to be coupled with a particular IOL that has curvature, the body 2104 can be provided with a corresponding amount of curvature along the mask axis 2136 that corresponds to the curvature. Likewise, the body 2104 can be provided with corresponding shape to accommodate IOL transition zones. Further details about the reduced thickness design are described in U.S. Pub. No. 2011/0040376, filed Aug. 13, 2010 and hereby incorporated by reference in its entirety.
In one embodiment, one of the anterior surface 2108 and the posterior surface 2112 of the body 2104 is substantially planar. In one planar embodiment, very little or no uniform curvature can be measured across the planar surface. In another embodiment, both of the anterior and posterior surfaces 2108, 2112 are substantially planar. In general, the thickness of the body 2104 of the mask 2100 can be within the range of from greater than zero to about 0.5 mm, about 1 micron to about 40 microns, and often in the range of from about 5 microns to about 20 microns. In some embodiments, the body 2104 of the mask 2100 has a thickness 2138 of at least about 5 microns and/or less than or equal to about 20 microns. In some embodiments, the body 2104 of the mask has a thickness 2138 of at least about 10 microns and/or less than or equal to about 15 microns. In certain embodiments, the thickness 2138 is about 15 microns. In certain embodiments, the thickness 2138 is about 10 microns. In certain embodiments, the thickness 2138 of the mask 2100 is about 5 microns. In another embodiment, the thickness 2138 of the mask 2100 is about 8 microns. In another embodiment, the thickness 2138 of the mask 2100 is about 10 microns.
A substantially planar mask has several advantages over a non-planar mask. For example, a substantially planar mask can be fabricated more easily than one that has to be formed to a particular curvature. In particular, the process steps involved in inducing curvature in the mask 2100 can be eliminated.
The aperture 2128 is configured to transmit substantially all incident light along the mask axis 2136. The non-transmissive portion 2132 surrounds at least a portion of the aperture 2128 and substantially prevents transmission of incident light thereon. As discussed in connection with the above masks, the aperture 2128 can be a through-hole in the body 2104 or a substantially light transmissive (e.g., transparent) portion thereof. The aperture 2128 of the mask 2100 generally is defined within the outer periphery 2124 of the mask 2100. The aperture 2128 can take any of suitable configurations, such as those described above.
In one embodiment, the aperture 2128 is substantially circular and is substantially centered in the mask 2100. The size of the aperture 2128 can be any size that is effective to increase the depth of focus of an eye of a patient with presbyopia. In particular, the size of the aperture 2128 is dependent on the location of the mask within the eye (e.g., distance from the retina). In some embodiments, the aperture 2128 can have a diameter of at least about 0.85 mm and/or less than or equal to about 2.2 mm. In certain embodiments, the diameter of the aperture 2128 is less than about 2 mm. In some embodiments, the diameter of the aperture is at least about 1.1 mm and/or less than or equal to about 1.6 mm. In a further embodiment, the diameter of the aperture is at least about 1.3 mm and/or less than or equal to about 1.4 mm.
In certain embodiments, the aperture 2128 includes an optical power and/or refractive properties. For example, the aperture 2128 can include an optic and can have an optical power (e.g. positive or negative optical power). In certain embodiments, the aperture 2128 can add to the active correction of the intraocular lens.
The non-transmissive portion 2132 is configured to prevent transmission of visible light through the mask 2100. For example, in one embodiment, the non-transmissive portion 2132 prevents transmission of substantially all of at least a portion of the spectrum of the incident visible light. In one embodiment, the non-transmissive portion 2132 is configured to prevent transmission of substantially all visible light, e.g., radiant energy in the electromagnetic spectrum that is visible to the human eye. The non-transmissive portion 2132 can substantially prevent transmission of radiant energy outside the range visible to humans in some embodiments.
As discussed above, preventing transmission of light through the non-transmissive portion 2132 decreases the amount of light that reaches the retina and the fovea that would not converge at the retina and fovea to form a sharp image. As discussed above, the size of the aperture 2128 is such that the light transmitted therethrough generally converges at the retina or fovea. Accordingly, a much sharper image is presented to the retina than would otherwise be the case without the mask 2100.
In one embodiment, the non-transmissive portion 2132 prevents transmission of at least about 90 percent of incident light. In another embodiment, the non-transmissive portion 2132 prevents transmission of at least about 95 percent of all incident light. The non-transmissive portion 2132 of the mask 2100 can be configured to be substantially opaque to prevent the transmission of light.
In some embodiments, the non-transmissive portion 2132 can transmit no more than about 5% of incident visible light. In some embodiments, the non-transmissive portion 2132 can transmit no more than about 3% of incident visible light. In some embodiments, the non-transmissive portion 2132 can transmit no more than about 2% of incident visible light. In one embodiment, at least a portion of the body 2104 is configured to be opaque to more than 99 percent of the light incident thereon.
As discussed above, the non-transmissive portion 2132 can be configured to prevent transmission of light without absorbing the incident light. For example, the mask 2100 could be made reflective or could be made to interact with the light in a more complex manner, as discussed in U.S. Pat. No. 6,554,424, issued Apr. 29, 2003, which is hereby incorporated by reference in its entirety.
As discussed above, the mask 2100 can include a plurality of holes 2120. The lens body can extend at least partially through the holes, thereby creating a bond (e.g. material “bridge”) between the lens body on either side of the mask.
The holes 2120 of the mask 2100 shown in
In some embodiments, the mask 2100 can include an annular region near the outer periphery 2124 of the mask having no holes. In certain embodiments, there are no holes within 0.1 mm of the outer periphery 2124 of the mask 2100.
In some embodiments, the mask can include an annular region around the inner periphery of the mask having no holes. In certain embodiments, there are no holes within 0.1 mm of the aperture 2128.
As shown in
In some embodiments, the holes are interspersed at irregular locations throughout at least a portion of the mask 2100. In some embodiments, holes of different diameters are evenly interspersed throughout at least a portion of the mask 2100. For example, the mask 2100 can include a plurality of non-overlapping hole regions. The sum of the surface area of the plurality of non-overlapping hole regions can equal to total surface area of the entire hole region of the mask. Each region of the plurality of regions can include a number of holes, each of the holes having a different diameter. The number of holes in each region can equal the number of different hole sizes in the entire hole region.
In some embodiments, there are at least about 1000 holes and/or less than or equal to about 2000 holes. In some embodiments, there are at least about 1000 holes and/or less than or equal to about 1100 holes. In some embodiments, there are about 1040 holes. In some embodiments, there are an equal number of holes of each diameter. In some embodiments, the number of holes having each diameter is different.
In certain embodiments, the free rotation of the photochromic chromophores can be prevented by using particular mask materials such as a photochromic polymer, wherein photochromic chromophores are contained within a polymer matrix. To further control the rotation of the photochromic chromophores, such a polymer matrix can have a controlled glass transition temperature (Tg), such that when heat is applied to the polymer matrix, the matrix undergoes a glass transition from a brittle to a more molten or rubber-like state. While in the more brittle state, the polymer matrix prevents free rotation of the photochromic chromophore, locking the photochromic chromophore into a colorless or a light-absorbing state. However, when in the less brittle, more molten state, the polymer matrix allows free rotation of the photochromic chromophore between colorless or light-absorbing states. Consequently, in this embodiment, a mask can be configured to switch between a state with one degree of opacity to a state with another degree of opacity, through the simple application of heat and activating light.
In some embodiments, a mask configured to controllably switch between different levels of opacity is advantageous because it can allow treatment providers to inspect the back of the eye without requiring the removal of the mask. Further, in certain embodiments, such a feature can allow for switchable changes in mask geometry from outside the eye, potentially allowing for the adjustment of the masks from a first opacity to a second different opacity for various treatments or performance objectives.
In some embodiments, the transition portion of the mask can comprise any proportion of the total mask, ranging from above 0% to 100% of the mask. For example, the transition portion can be at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 90%, or about 100% of the total area of the opaque portion of the mask.
In certain embodiments, the transition portion can switch between a first level of opacity that blocks the transmittance of substantially all light and a second level of opacity where substantially all light can pass through the mask. In some embodiments, the mask can be configured to switch between any level of opacity ranging from above 0 to 100%, corresponding to blocking between 0% to 100% of visible light, respectively. For example, the change in the level of opacity between the first level and the second level can be at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or more.
For example, referring to
In one implementation of the invention, the outer annular ring 5016 comprises a fixed opacity. The inner ring 5014 comprises a transition portion as described elsewhere herein. The opacity of the transition portion may be adjusted between a first opacity that is relatively high, such as substantially equivalent to the opacity of the outer zone 5016, and a reduced opacity as described elsewhere herein. In effect, the invention enables the provision of a mask 5010 having an aperture 5012 of a first diameter. Adjustment of the opacity of the inner ring 5014 from a relatively high opacity to a relatively low opacity has the effect of increasing the diameter of the central aperture 5012. This may be desirable for altering the optical characteristics of the mask, or for increasing the visual access to the interior of the eye for diagnostic or therapeutic purposes.
Alternatively, the relationship between the fixed ring and the variable ring may be reversed. Thus, the inner ring 5014 may be provided with a permanent opacity. The outer ring 5016 may be provided with a variable characteristic such that the opacity may be changed between a relatively low level and a relatively high level.
In general, the mask of the present invention may be provided on an intraocular lens, a corneal inlay, or elsewhere along the optical path. It may be provided with at least a first region having a predetermined transmission characteristic, and at least a second region having a controllable variable transmission characteristic.
The variable opacity characteristic can be accomplished by any of a variety of systems in which a change in opacity may be accomplished in response to exposure to an external stimulus. The external stimulus can be ultraviolet, visible or infrared light, heat, a radiofrequency or magnetic field, electrical current, mechanical vibration (e.g. ultrasound) or other triggering signal that can be applied to the eye. Certain chemical systems which respond to an exposure to light will be described further herein.
As described above, in some embodiments, the mask contains at least one transition portion with photochromic chromophores contained within a polymer matrix. In a preferred embodiment, the photochromic chromophore is spiropyran, although other photochromic chromophores can be used. For example, any photochromic chromophore that undergoes a stereochemical conformational change that can be locked within a polymer matrix can be used. In certain embodiments, the photochromic chromophore or other compound can be any suitable molecule or compound that can be bound into a polymer chain. Further suitable chromophores include, but are not limited to: naphthopyrans, chromenes, fulgides, similar molecules, and mixtures thereof. In other embodiments, dimers of the photochromic chromophore can be used such as, for example, a spiropyran dimer. Desirably, in embodiments, the photochromic chromophore or compound is one that can easily rearrange in the photochromic polymer to alter the transmission state when exposed to suitable irradiation and heat, but which is more difficult to rearrange in the photochromic polymer to alter the transmission state when heat is removed. For example, further details concerning the use of photochromic chromophores within a polymer matrix can be found in U.S. Pat. No. 8,216,765, entitled “REIMAGEABLE AND REUSABLE MEDIUM AND METHOD OF PRODUCING AND USING THE REIMAGEABLE AND REUSABLE MEDIUM,” filed Mar. 9, 2009. and which is hereby incorporated by reference in its entirety.
In certain embodiments, the photochromic chromophore concentration within the polymer matrix of the transition portion can be varied to result in a range of switchable opacities. For example, the concentration of photochromic chromophore can be varied to produce a switchable level of opacity within the transition portion having a change in transmission of at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least 50%, at least about 60%, at least about 70%, or more between the high transmission and low transmission states.
In some embodiments, the photochromic chromophore can be distributed homogenously throughout the transition portions of the mask, resulting in a constant level of opacity across the transition portions of the mask. In certain embodiments, the photochromic chromophore can be distributed heterogeneously throughout the transition portions of the mask, resulting in a non-constant level of opacity across the transition portions of the mask.
In some embodiments, the wavelength of light used to activate the photochromic chromophore to switch from a colorless or high transmission state to an opaque or relatively lower transmission state can be any wavelength of light capable of triggering an absorption transition. In certain embodiments, the wavelength of light used to activate the photochromic chromophore to switch from a colorless state to an opaque state is in the ultraviolet range. In further embodiments, the wavelength of light used to activate the photochromic chromophore is in the infrared range. In additional embodiments, the wavelength of light used to activate the photochromic chromophores is in the visible light range.
In certain embodiments, the photochromic chromophore contained within the transition portion of the mask can be selected so as to allow for exposure to selected events such as illumination and imaging via a camera without activating the photochromic chromophore. For example, the wavelength of light used by the camera to illuminate and image the mask can be of such a different wavelength of light from the activating wavelength of the photochromic chromophore that the light from the camera will not activate the photochromic chromophore. In some embodiments, near infrared light could be used by the camera, while ultraviolet light is used for the photochromic chromophore.
In certain embodiments, the wavelength of energy used by the illuminating and imaging camera is the same as the wavelength of energy used to heat the system. In some embodiments, the wavelength of energy used by the camera is different from the wavelength of energy used to heat the system.
As described above, in some embodiments, the transition portions of the mask contain light-activated photochromic chromophores contained within a polymer matrix with a controlled Tg. In some embodiments, the photochromic chromophore is polymerized directly into the backbone of the polymer used in the polymer matrix. Suitable photochromic chromophores are described above, however, in some embodiments suitable polymers can be formed from first and second monomers. For example, further details concerning the formation of first and second monomers and incorporation of a photochromic chromophore into a polymer matrix can be found in U.S. Pat. No. 8,216,765, entitled “REIMAGEABLE AND REUSABLE MEDIUM AND METHOD OF PRODUCING AND USING THE REIMAGEABLE AND REUSABLE MEDIUM,” filed Mar. 9, 2009 and which was incorporated by reference above.
In certain embodiments, the photochromic polymer is optionally dissolved or dispersed in any suitable carrier, such as a solvent, a polymer binder, or the like. Water may be used as a solvent for water soluble photochromic polymers and water-soluble binders such as poly(vinyl alcohol) and poly(acrylic acid). Other suitable solvents include, for example, straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons, and the like, such as where the straight or branched chain aliphatic hydrocarbons have from about 1 to about 30 carbon atoms. For example, a non-polar liquid of the ISOPAR™ series (manufactured by the Exxon Corporation) may be used as the solvent. These hydrocarbon liquids are considered narrow portions of iso-paraffinic hydrocarbon fractions. Other suitable solvent materials include, for example, the NORPAR™ series of liquids, which are compositions of n-paraffins available from Exxon Corporation, the SOLTROL™ series of liquids available from the Phillips Petroleum Company, and the SHELLSOL™ series of liquids available from the Shell Oil Company. Mixtures of one or more solvents, i.e., a solvent system, can also be used, if desired. In addition, more polar solvents can also be used, if desired. Examples of more polar solvents that may be used include halogenated and nonhalogenated solvents, such as tetrahydrofuran, trichloro- and tetrachloroethane, dichloromethane, chloroform, monochlorobenzene, toluene, xylenes, acetone, methanol, ethanol, xylenes, benzene, ethyl acetate, dimethylformamide, cyclohexanone, N-methyl acetamide and the like. The solvent may be composed of one, two, three or more different solvents. When two or more different solvents are present, each solvent may be present in an equal or unequal amount by weight ranging for example from about 5% to 90%, particularly from about 30% to about 50%, based on the weight of all solvents.
In some embodiments, the photochromic polymer can be dispersed in another, non-photochromic polymer binder. Such an additional polymer binder may be desired, for example, depending on the properties, characteristics, and the like of the photochromic polymer. Of course, it will be understood that an additional polymer binder may not be required in some embodiments, as the photochromic polymer can itself function as a binder material. Suitable examples of polymer binders that can be used include, but are not limited to, polyalkylacrylates like polymethyl methacrylate (PMMA), polycarbonates, polyethylenes, oxidized polyethylene, polypropylene, polyisobutylene, polystyrenes, poly(styrene)-co-(ethylene), polysulfones, polyethersulfones, polyarylsulfones, polyarylethers, polyolefins, polyacrylates, polyvinyl derivatives, cellulose derivatives, polyurethanes, polyamides, polyimides, polyesters, silicone resins, epoxy resins, polyvinyl alcohol, polyacrylic acid, and the like. Copolymer materials such as polystyrene-acrylonitrile, polyethylene-acrylate, vinylidenechloride-vinylchloride, vinylacetate-vinylidene chloride, styrene-alkyd resins are also examples of suitable binder materials. The copolymers may be block, random, or alternating copolymers. In some embodiments, polymethyl methacrylate or a polystyrene is the polymer binder, in terms of their cost and wide availability. The polymer binder, when used, has the role to provide a coating or film forming composition.
Phase change materials can also be used as the polymer binder. Phase change materials are known in the art, and include for example crystalline polyethylenes such as Polywax® 2000, Polywax® 1000, Polywax® 500, and the like from Baker Petrolite, Inc.; oxidized wax such as X-2073 and Mekon wax, from Baker-Hughes Inc.; crystalline polyethylene copolymers such as ethylene/vinyl acetate copolymers, ethylene/vinyl alcohol copolymers, ethylene/acrylic acid copolymers, ethylene/methacrylic acid copolymers, ethylene/carbon monoxide copolymers, polyethylene-b-polyalkylene glycol wherein the alkylene portion can be ethylene, propylene, butylenes, pentylene or the like, and including the polyethylene-b-(polyethylene glycol)s and the like; crystalline polyamides; polyester amides; polyvinyl butyral; polyacrylonitrile; polyvinyl chloride; polyvinyl alcohol hydrolyzed; polyacetal; crystalline poly(ethylene glycol); poly(ethylene oxide); poly(ethylene therephthalate); poly(ethylene succinate); crystalline cellulose polymers; fatty alcohols; ethoxylated fatty alcohols; and the like, and mixtures thereof.
In some embodiments, any suitable polymer that has one or more photochromic molecules or compounds bound to the polymer backbone, can be used. Such photochromic polymers can have the photochromic molecules or compounds covalently bound to the polymer backbone within the polymer chain itself. Such groups can be introduced into the polymer chain, for example, by including the photochromic molecules or compounds during the polymer preparation process, such as in the form of reactive units, monomer units, or the like, or they can be added to an already formed non-photochromic polymer material through known chemical functionalization reactions.
Where multiple photochromic molecules or compounds are present in the polymer chain, the multiple photochromic molecules or compounds can be the same or different. Likewise, the photochromic polymer can include only one type of photochromic polymer, or can include a mixture of two or more different types of photochromic polymer (such as different photochromic polymers having different photochromic molecules or compounds in the polymer chain, or the same or different photochromic molecules or compounds in different polymer chains. Because the photochromic polymer is converted between its colored and colorless states by the use of light and heat, the polymer and photochromic molecules or compounds are desirably selected such that the photochromic polymer has thermal properties that can withstand the elevated temperatures that may be used.
In certain embodiments, a photochromic polymer containing a photochromic chromophore within a polymer backbone is mixed with a second miscible polymer with side-chain crystallizable side groups such as polyoctadecyl acrylate. For example, further details concerning side-chain crystallizable polymers can be found in U.S. Pat. No. 4,830,855, entitled “TEMPERATURE-CONTROLLED ACTIVE AGENT DISPENSER,” filed Nov. 13, 1987 and which is hereby incorporated by reference in its entirety. In certain embodiments, the photochromic chromophore can be polymerized directly into side-chain crystallizable polymers. In certain embodiments, the first and/or second monomers described above can be side-chain crystallizable polymers.
In some embodiments, the length of the side-chain moiety is usually greater than 5 times the distance between side-chains in the case of acrylates, methacrylates, vinyl esters, acrylamides, methacrylamides, vinyl ethers and alpha olefins. In certain embodiments, a fluoroacrylate alternate copolymer with butadiene as the side-chain can be as little as 2 times the length as the distance between branches. In some embodiments, the side-chain units should make up greater than 50% of the volume of the polymer, preferably greater than 65% of the volume. Co-monomers added to a side-chain polymer usually have an adverse effect on crystallinity. Small amounts of various co-monomers can be tolerated, usually up to 10 to 25 volume percent. In some embodiments, it is desirable to add small amounts of co-monomer, for example cure site monomers such as acrylic acid, glycidal methacrylate, maleic anhydride, amino function monomer and the like. Specific examples of side-chain crystallizable monomers are the acrylate, fluoroacrylate, methacrylate and vinyl ester polymers described in J. Poly. Sci. (1972) 10:50 3347; J. Poly. Sci. (1972) 10: 1657; J. Poly. Sci. (1971) 9:3367; J. Poly. Sci. (1971) 9: 3349; J. Poly. Sci. (1971) 9:1835; J.A.C.S. (1954) 76: 6280; J. Poly. Sci. (1969) 7: 3053; Polymer J. (1985) 17: 991. corresponding acrylamides, substituted acrylamide and maleimide polymers (J. Poly. Sci., Poly. Physics Ed. (1980) 18: 2197; polyalphaolefin polymers such as those described in J. Poly. Sci.: Macromol. Rev. (1974) 8: 117-253 and Macromolecules (1980) 13: 12, polyalkylvinylethers, polyalkylethylene oxides such as those described in Macromolecules (1980) 13: 15, alkylphosphazene polymers, polyamino acids such as those described in Poly. Sci. USSR (1979) 21: 241, Macromolecules (1985) 18: 2141, polyisocyanates such as those described in Macromolecules (1979) 12: 94. polyurethanes made by reacting amine- or alcohol-containing monomers with long chain alkyl isocyanates, polyesters and poly ethers. Polysiloxanes and polysilanes such as those described in Macromolecules (1986) 19: 611 and p-alkylstyrene polymers such as those described in J.A.C.S. (1953) 75: 3326 and J. Poly. Sci. (1962) 60: 19.
In certain embodiments, the photochromic chromophore can be incorporated into a polyester polycondensate. For example, further details concerning this type of incorporation can be found in U.S. Pat. No. 3,918,972, entitled “IMAGING PROCESS UTILIZING A POLYESTER POLYCONDENSATE CONTAINING SPIROPYRAN PHOTOCHROMIC GROUPS” filed Aug. 13, 1973 and hereby incorporated by reference in its entirety. Further details concerning additional photochromic polycondensates can be found in U.S. Pat. No. 4,026,869 entitled PHOTOCHROMIC POLYCONDENSATES, filed Jul. 21, 1975 and hereby incorporated by reference in its entirety.
In some embodiments, linear polycondensates of the polyester type are provided characterized in that they contain spiropyran photochromic groups as an integral part of the main polymer chain. In certain embodiments, they can be prepared by polycondensation of Bisphenol-A and a photochromic compound carrying a hydroxyalkyl group on either side of the photochromic moiety, with a dicarboxylic acid of the saturated dicarboxylic acid series, preferably with succinic acid, adipic acid, glutaric acid and pimelic acid. In this process the dicarboxylic acid in the form of a diacid dichloride is dissolved in an organic liquid, such as methylene chloride, dichloroethane, tetrachloroethane, benzene or toluene, which is also a solvent for the copolycondensate to be formed. The bisphenol is dissolved in another liquid, which is immiscible with the above organic liquid. Preferably water is used as a solvent for the bisphenol and an equivalent amount of a metal hydroxide, such as sodium hydroxide or potassium hydroxide is added to the water in order to form immediately the corresponding diphenolate. The reaction speed is greatly increased by using quaternary ammonium compounds as catalysts. The two solutions are mixed and stirred vigorously at the reaction temperature, whereby the copolyester is formed in solution. In the same way the photochromic copoly-condensates of the invention are formed. In some embodiments, a photochromic compound carrying on either side of the photochromic moiety an hydroxyalkylgroup is made to react with an excess of the diacid dichloride e.g. of succinic acid, adipic acid, glutaric acid, or pimelic acid, and the photochrome-bis-acid chloride formed in this way is made to react in a two-phase reaction mixture with a diphenolate of bisphenol-A. Suitable photochromic compounds carrying two hydroxyalkyl groups on either side of the photochromic moiety are compounds, containing spiropyran groups.
In certain embodiments, the photochromic chromophore is directly polymerized into a polymer backbone as described above and mixed with the miscible polymer combination described above. In some embodiments, the photochromic dye is directly polymerized into the polymer backbone of a polymer that also has side chain crystallizable side groups such as described above. In certain embodiments, the photochromic oligomers or monomers described above and in U.S. Pat. No. 8,216,765 can be mixed with the aforementioned miscible combination of polymers. In some embodiments, a dimer of any of the aforementioned photochromic chromophores can be mixed with any of the aforementioned polymers.
In further embodiments, the Tg of the polymer matrix can be between 30°-150° C. For example, the Tg can be at least about 30° C., about 35° C., about 40° C., about 45° C., about 50° C., about 55° C., about 60° C., about 65° C., about 70° C., about 75° C., about 80° C., about 85° C., about 90° C., about 95° C., about 100° C., about 105° C., about 110° C., about 115° C., about 120° C., about 125° C., about 130° C., about 135° C., about 140° C., about 145° C., or about 150° C.
The Tg of the polymer matrix can be varied by changing the chemical properties of the polymers comprising the polymer matrix. In some embodiments, the Tg of the polymer matrix can be modified by varying the chain length of the monomer used in polymerization. In further embodiments, the Tg is controlled by varying the chain length of the side groups that branch from the polymer backbone. In other embodiments, the Tg of the polymer matrix can be adjusted by varying the spacing between the side-chains. In certain embodiments, the Tg of the polymer is controlled by varying the cross-link density of the polymer. In other embodiments, the Tg of the polymer can be controlled by varying the molecular weight of the polymer. Any of the aforementioned polymer properties can be adjusted together or separately to tune the Tg of the polymer matrix.
As described previously, in some embodiments, heat can be used to cause the polymer matrix to undergo a glass transition. In certain embodiments, heat is provided to the polymer matrix via focused radiant energy from outside the eye. For example, this focused radiant energy can be a laser. In some embodiments, ultrasonic energy can be applied to the mask to heat it. In some embodiments, heat or other initiator is applied to the transition portions, or to one of multiple transition portions of the mask.
In some embodiments, an axicon lens can be used to focus a circular beam of radiant energy into the eye and onto a mask to heat an annular area of the mask inside the eye. In certain embodiments, the annular pattern created by the axicon lens can be focused further before entering the eye to create a confocal focusing of the annular pattern to bring it to a smaller, higher energy density annular region of focus inside the eye on the mask. In certain embodiments, a biconvex toric lens could be used to achieve the confocal focusing of the annular pattern output from the axicon lens element to focus it confocally into the eye. In some embodiments, other optical configurations instad of an axicon lens can be used to provide a confocally focused annular beam of energy into the eye.
In some embodiments, focusing of the radiant energy into the eye and onto the mask would be completed with simultanous microscope viewing for better control and monitoring of the procedure inside the eye. This arrangement is advantageous, as the focus of the radiation area on the mask and the change of the photochromic chromophores in this area could be directly observed.
While the above detailed description has shown, described, and pointed out novel features as applied to various embodiments, it will be understood that various omissions, substitutions, and changes in the form and details of the device or process illustrated can be made without departing from the spirit of the disclosure. As will be recognized, certain embodiments of the inventions described herein can be embodied within a form that does not provide all of the features and benefits set forth herein, as some features can be used or practiced separately from others. The scope of the inventions is indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.
This application is a continuation of U.S. application Ser. No. 16/511,437, filed Jul. 15, 2019, which is a continuation of U.S. application Ser. No. 15/436,150 filed Feb. 17, 2017, which is a continuation of U.S. application Ser. No. 14/961,308, filed Dec. 7, 2015, now issued as U.S. Pat. No. 9,603,704, which is a divisional of U.S. application Ser. No. 13/802,340, filed Mar. 13, 2013, now issued as U.S. Pat. No. 9,204,962. The entire contents of the aforementioned application and patent are hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
564518 | Heilborn | Jul 1896 | A |
1034516 | Samberg | Aug 1912 | A |
1206132 | Otte | Nov 1916 | A |
1959915 | Guthrie | May 1934 | A |
2129305 | Feinbloom | Sep 1938 | A |
2350421 | Schoder et al. | Jun 1944 | A |
2470927 | Hale, Jr. | May 1949 | A |
2714721 | Stone, Jr. | Aug 1955 | A |
3034403 | Neefe | May 1962 | A |
3074407 | Moon et al. | Jan 1963 | A |
3270099 | Camp | Aug 1966 | A |
3339997 | Wesley | Sep 1967 | A |
3392727 | Hanlon | Jul 1968 | A |
D212868 | Olson | Dec 1968 | S |
3458870 | Stone, Jr. | Aug 1969 | A |
3507566 | Knapp | Apr 1970 | A |
3536386 | Spivack | Oct 1970 | A |
3578850 | Grant | May 1971 | A |
3600098 | Mohrman | Aug 1971 | A |
3726587 | Kendall | Apr 1973 | A |
3776230 | Neefe | Dec 1973 | A |
3794414 | Wesley | Feb 1974 | A |
3852032 | Urbach | Dec 1974 | A |
3877502 | Hunckler | Apr 1975 | A |
3914013 | Rosenberg | Oct 1975 | A |
3918972 | Evens et al. | Nov 1975 | A |
3946982 | Calkins et al. | Mar 1976 | A |
3982541 | L'Esperance, Jr. | Sep 1976 | A |
4010496 | Neefe | Mar 1977 | A |
4026869 | Evens et al. | May 1977 | A |
4073015 | Peyman | Feb 1978 | A |
4099529 | Peyman | Jul 1978 | A |
4116439 | Chavarria et al. | Sep 1978 | A |
4138191 | Peyman | Feb 1979 | A |
4191195 | Miller | Mar 1980 | A |
4210391 | Cohen | Jul 1980 | A |
4272191 | Bergkvist | Jun 1981 | A |
4298004 | Schchar et al. | Nov 1981 | A |
4312575 | Peyman et al. | Jan 1982 | A |
4340283 | Cohen | Jul 1982 | A |
4367949 | Lavering | Jan 1983 | A |
4383843 | Lyenger | May 1983 | A |
4402579 | Poler | Sep 1983 | A |
4402681 | Haas et al. | Sep 1983 | A |
4409979 | Roussel et al. | Oct 1983 | A |
4423728 | Lieberman | Jan 1984 | A |
4445892 | Hussein et al. | May 1984 | A |
4450593 | Poler | May 1984 | A |
4452235 | Reynolds | Jun 1984 | A |
4461294 | Baron | Jul 1984 | A |
4469098 | Daui | Sep 1984 | A |
4485499 | Castleman | Dec 1984 | A |
4505855 | Bruns et al. | Mar 1985 | A |
4528311 | Beard et al. | Jul 1985 | A |
4536240 | Winn | Aug 1985 | A |
4538608 | L'Esperance, Jr. | Sep 1985 | A |
4547914 | Castleman | Oct 1985 | A |
4547915 | Castleman | Oct 1985 | A |
4563565 | Kampfer et al. | Jan 1986 | A |
4573998 | Mazzocco | Mar 1986 | A |
4575373 | Johnson | Mar 1986 | A |
4575915 | Clark et al. | Mar 1986 | A |
4576453 | Borowsky | Mar 1986 | A |
4582402 | Knapp | Apr 1986 | A |
4607617 | Choyce | Aug 1986 | A |
4612012 | White | Sep 1986 | A |
4615702 | Koziol et al. | Oct 1986 | A |
4617023 | Peyman | Oct 1986 | A |
4624669 | Grendahl | Nov 1986 | A |
4633866 | Peyman et al. | Jan 1987 | A |
4636049 | Blaker | Jan 1987 | A |
4636211 | Nielsen et al. | Jan 1987 | A |
4636212 | Posin et al. | Jan 1987 | A |
4637697 | Freeman | Jan 1987 | A |
4639105 | Neefe | Jan 1987 | A |
4641934 | Freeman | Feb 1987 | A |
4642112 | Freeman | Feb 1987 | A |
4646720 | Peyman | Mar 1987 | A |
4648400 | Schneider et al. | Mar 1987 | A |
4655774 | Choyce | Apr 1987 | A |
4662370 | Hoffman et al. | May 1987 | A |
4665913 | L'Esperance, Jr. | May 1987 | A |
4666249 | Bauman et al. | May 1987 | A |
4666446 | Koziol et al. | May 1987 | A |
4669466 | L'Esperance, Jr. | Jun 1987 | A |
4669834 | Richter | Jun 1987 | A |
4672021 | Blumel et al. | Jun 1987 | A |
4674503 | Peyman et al. | Jun 1987 | A |
4676790 | Kern | Jun 1987 | A |
4676791 | Le Master et al. | Jun 1987 | A |
4678422 | York | Jul 1987 | A |
4685921 | Peyman | Aug 1987 | A |
4685922 | Peyman | Aug 1987 | A |
4701038 | Neefe | Oct 1987 | A |
4702574 | Bawa | Oct 1987 | A |
4702865 | Koziol et al. | Oct 1987 | A |
4704016 | de Carle | Nov 1987 | A |
4710003 | Masuda et al. | Dec 1987 | A |
4713446 | DeVore et al. | Dec 1987 | A |
4715858 | Lindstrom | Dec 1987 | A |
4718418 | L'Esperance | Jan 1988 | A |
4729372 | L'Esperance, Jr. | Mar 1988 | A |
4729373 | Peyman | Mar 1988 | A |
4732148 | L'Esperance, Jr. | Mar 1988 | A |
4744360 | Bath | May 1988 | A |
4753654 | Posin et al. | Jun 1988 | A |
4767647 | Bree | Aug 1988 | A |
4779973 | Miller et al. | Oct 1988 | A |
4785796 | Mattson | Nov 1988 | A |
4785810 | Baccala et al. | Nov 1988 | A |
4787903 | Grendahl | Nov 1988 | A |
4795462 | Grendahl | Jan 1989 | A |
4796623 | Krasner et al. | Jan 1989 | A |
4798608 | Grendahl | Jan 1989 | A |
4799478 | Fedorov et al. | Jan 1989 | A |
4799784 | Safir | Jan 1989 | A |
4799931 | Lindstrom | Jan 1989 | A |
4799973 | Lindstrom | Jan 1989 | A |
4806382 | Goldberg et al. | Feb 1989 | A |
4807623 | Lieberman | Feb 1989 | A |
4808181 | Kelman | Feb 1989 | A |
4813955 | Achatz et al. | Mar 1989 | A |
4814050 | McGraw et al. | Mar 1989 | A |
4817789 | Paul | Apr 1989 | A |
4830855 | Stewart | May 1989 | A |
4838266 | Koziol et al. | Jun 1989 | A |
4840175 | Peyman | Jun 1989 | A |
4842599 | Bronstein | Jun 1989 | A |
4849323 | Endo et al. | Jul 1989 | A |
4851003 | Lindstrom | Jul 1989 | A |
4856234 | Goins | Aug 1989 | A |
4863466 | Schlegel | Sep 1989 | A |
4865601 | Caldwell et al. | Sep 1989 | A |
4869587 | Breger | Sep 1989 | A |
4878910 | Koziol et al. | Nov 1989 | A |
4881860 | Kanazawa | Nov 1989 | A |
4881954 | Bikson et al. | Nov 1989 | A |
4889795 | Kaifu et al. | Dec 1989 | A |
4890913 | De Carle | Jan 1990 | A |
4891043 | Zeimer et al. | Jan 1990 | A |
4892543 | Turley | Jan 1990 | A |
4898461 | Portney | Feb 1990 | A |
4903695 | Warner et al. | Feb 1990 | A |
4907586 | Bille et al. | Mar 1990 | A |
4923297 | Arndt | May 1990 | A |
4928815 | Paul | May 1990 | A |
4932970 | Portney | Jun 1990 | A |
4955904 | Atebara et al. | Sep 1990 | A |
4958922 | Binh et al. | Sep 1990 | A |
4959070 | McDonald | Sep 1990 | A |
4961744 | Kilmer et al. | Oct 1990 | A |
4965545 | Johnson | Oct 1990 | A |
4971432 | Koeniger | Nov 1990 | A |
4976709 | Sand | Dec 1990 | A |
4976732 | Vorosmarthy | Dec 1990 | A |
4983181 | Civerchia | Jan 1991 | A |
4985559 | Goldberg et al. | Jan 1991 | A |
4990165 | Bikson et al. | Feb 1991 | A |
4994058 | Raven et al. | Feb 1991 | A |
4994080 | Shepard | Feb 1991 | A |
4997268 | Dauvergne | Mar 1991 | A |
5002571 | O'Donnel, Jr. | Mar 1991 | A |
5013319 | Davis | May 1991 | A |
5019097 | Knight et al. | May 1991 | A |
5021196 | Crano et al. | Jun 1991 | A |
5026393 | Mackool | Jun 1991 | A |
D318117 | Michelson | Jul 1991 | S |
5030230 | White | Jul 1991 | A |
5041133 | Sayano et al. | Aug 1991 | A |
5055602 | Melpolder | Oct 1991 | A |
5061914 | Busch et al. | Oct 1991 | A |
5063942 | Kilmer et al. | Nov 1991 | A |
5065516 | Dulebohn | Nov 1991 | A |
5067961 | Kelman et al. | Nov 1991 | A |
5076684 | Simpson et al. | Dec 1991 | A |
D323891 | Arkel | Feb 1992 | S |
5087015 | Galley | Feb 1992 | A |
5089022 | Koester et al. | Feb 1992 | A |
5089024 | Christie et al. | Feb 1992 | A |
5090955 | Simon | Feb 1992 | A |
5092874 | Rogers | Mar 1992 | A |
5094521 | Jolson et al. | Mar 1992 | A |
5098443 | Parel et al. | Mar 1992 | A |
5098444 | Feaster | Mar 1992 | A |
D325500 | Dennis | Apr 1992 | S |
5104957 | Kelman et al. | Apr 1992 | A |
5108169 | Mandell | Apr 1992 | A |
5108427 | Majercik et al. | Apr 1992 | A |
5108428 | Capecchi et al. | Apr 1992 | A |
5112328 | Taboada et al. | May 1992 | A |
5112350 | Civerchia et al. | May 1992 | A |
5116111 | Simpson et al. | May 1992 | A |
5119555 | Johnson | Jun 1992 | A |
5120120 | Cohen | Jun 1992 | A |
5120121 | Rawlings et al. | Jun 1992 | A |
5123921 | Werblin et al. | Jun 1992 | A |
5133745 | Falcetta et al. | Jul 1992 | A |
5139518 | White | Aug 1992 | A |
5149331 | Ferdman et al. | Sep 1992 | A |
5151098 | Loertascher | Sep 1992 | A |
5152789 | Willis | Oct 1992 | A |
5156622 | Thompson | Oct 1992 | A |
5158572 | Nielsen | Oct 1992 | A |
5160463 | Evans et al. | Nov 1992 | A |
5165897 | Johnson | Nov 1992 | A |
5166712 | Portney | Nov 1992 | A |
5171318 | Gibson et al. | Dec 1992 | A |
5172143 | Baude et al. | Dec 1992 | A |
5185152 | Peyman | Feb 1993 | A |
5188125 | Kilmer et al. | Feb 1993 | A |
5188494 | Hatin | Feb 1993 | A |
5192316 | Ting | Mar 1993 | A |
5192318 | Schneider et al. | Mar 1993 | A |
5196026 | Barrett et al. | Mar 1993 | A |
5196027 | Thompson et al. | Mar 1993 | A |
5201762 | Hauber | Apr 1993 | A |
5203865 | Siepser | Apr 1993 | A |
5215104 | Steinert | Jun 1993 | A |
5219844 | Peyman et al. | Jun 1993 | A |
5225858 | Portney | Jul 1993 | A |
5239066 | Falkow et al. | Aug 1993 | A |
5245367 | Miller et al. | Sep 1993 | A |
5245738 | Johnson | Sep 1993 | A |
5258412 | Peyman et al. | Nov 1993 | A |
5260727 | Oksman et al. | Nov 1993 | A |
5261997 | Inselmann | Nov 1993 | A |
5269795 | Arnott | Dec 1993 | A |
5269812 | White | Dec 1993 | A |
5270744 | Portney | Dec 1993 | A |
5274404 | Michael | Dec 1993 | A |
5282971 | Degen et al. | Feb 1994 | A |
5288293 | O'Donnel, Jr. | Feb 1994 | A |
5288436 | Liu et al. | Feb 1994 | A |
5290301 | Lieberman | Mar 1994 | A |
5292514 | Capecchi et al. | Mar 1994 | A |
5296305 | Baude et al. | Mar 1994 | A |
5296881 | Freeman | Mar 1994 | A |
D345796 | Pernicka | Apr 1994 | S |
5300116 | Chirila et al. | Apr 1994 | A |
5300118 | Silvestrini et al. | Apr 1994 | A |
5302978 | Evans et al. | Apr 1994 | A |
5306297 | Rheinish et al. | Apr 1994 | A |
5310654 | Isberg et al. | May 1994 | A |
5312330 | Klopotek | May 1994 | A |
5312393 | Mastel | May 1994 | A |
5312424 | Kilmer et al. | May 1994 | A |
5314439 | Sugita | May 1994 | A |
5314961 | Anton et al. | May 1994 | A |
5315344 | Clark et al. | May 1994 | A |
5318044 | Kilmer et al. | Jun 1994 | A |
5318046 | Rozakis | Jun 1994 | A |
5318047 | Davenport et al. | Jun 1994 | A |
5322649 | Rheinish et al. | Jun 1994 | A |
5323788 | Silvestrini et al. | Jun 1994 | A |
5325880 | Johnson et al. | Jul 1994 | A |
5332802 | Kelman et al. | Jul 1994 | A |
5336261 | Barret et al. | Aug 1994 | A |
5346689 | Peyman et al. | Sep 1994 | A |
5354331 | Scharcar | Oct 1994 | A |
5358520 | Patel | Oct 1994 | A |
5366499 | Py | Nov 1994 | A |
5368604 | Kilmer et al. | Nov 1994 | A |
5372580 | Simon et al. | Dec 1994 | A |
5374272 | Arpa et al. | Dec 1994 | A |
D354566 | Donahoo | Jan 1995 | S |
5391201 | Barret et al. | Feb 1995 | A |
5401508 | Manesis | Mar 1995 | A |
5403335 | Loomas et al. | Apr 1995 | A |
5405384 | Silvestrini | Apr 1995 | A |
5414477 | Jahnke | May 1995 | A |
5422424 | Selsted et al. | Jun 1995 | A |
5433745 | Graham et al. | Jul 1995 | A |
5434630 | Bransome | Jul 1995 | A |
5437274 | Khoobehl et al. | Aug 1995 | A |
5441511 | Hanna | Aug 1995 | A |
5458819 | Chirila et al. | Oct 1995 | A |
5466260 | Silvestrini et al. | Nov 1995 | A |
5474548 | Knopp et al. | Dec 1995 | A |
5475452 | Kuhn et al. | Dec 1995 | A |
5476515 | Kelman et al. | Dec 1995 | A |
5480427 | Kelman et al. | Jan 1996 | A |
5489300 | Capecchi et al. | Feb 1996 | A |
5496339 | Koepnick | Mar 1996 | A |
5505722 | Kilmer et al. | Apr 1996 | A |
5505723 | Muller | Apr 1996 | A |
5507740 | O'Donnel, Jr. | Apr 1996 | A |
5507741 | L'Esperance, Jr. | Apr 1996 | A |
5507759 | Nordan | Apr 1996 | A |
5509922 | Aranyi et al. | Apr 1996 | A |
5516467 | Niwa et al. | May 1996 | A |
5516522 | Peyman et al. | May 1996 | A |
5522888 | Civerchia | Jun 1996 | A |
5526178 | Goldstein et al. | Jun 1996 | A |
5527356 | Peyman et al. | Jun 1996 | A |
5527524 | Tomalla et al. | Jul 1996 | A |
5547468 | Simon et al. | Aug 1996 | A |
5547473 | Peyman | Aug 1996 | A |
5567365 | Weinschenk, III et al. | Oct 1996 | A |
D375245 | Irving | Nov 1996 | S |
5571177 | Deacon et al. | Nov 1996 | A |
5579063 | Magnante et al. | Nov 1996 | A |
RE35421 | Ruiz et al. | Jan 1997 | E |
5591185 | Kilmer et al. | Jan 1997 | A |
5592246 | Kuhn et al. | Jan 1997 | A |
5599341 | Mathis et al. | Feb 1997 | A |
5599537 | Miller, III et al. | Feb 1997 | A |
5605938 | Roufa et al. | Feb 1997 | A |
5607437 | Simon et al. | Mar 1997 | A |
5607472 | Thompson | Mar 1997 | A |
5608471 | Miller | Mar 1997 | A |
5610719 | Allen et al. | Mar 1997 | A |
5624456 | Hellenkamp | Apr 1997 | A |
5627613 | Kaneko | May 1997 | A |
5628794 | Lindstrom | May 1997 | A |
5628795 | Langerman | May 1997 | A |
5628798 | Eggleston et al. | May 1997 | A |
5631243 | Kelman et al. | May 1997 | A |
5632773 | Graham et al. | May 1997 | A |
5643249 | Amano et al. | Jul 1997 | A |
5645582 | Silvestrini et al. | Jul 1997 | A |
5647865 | Swinger | Jul 1997 | A |
5653752 | Silvestrini et al. | Aug 1997 | A |
5662706 | Legerton et al. | Sep 1997 | A |
5662908 | Falkow et al. | Sep 1997 | A |
5672885 | Allen et al. | Sep 1997 | A |
5674724 | Miller, III et al. | Oct 1997 | A |
5674736 | Miller, III et al. | Oct 1997 | A |
5693092 | Silvestrini et al. | Dec 1997 | A |
5695983 | Miller et al. | Dec 1997 | A |
5697923 | Poler | Dec 1997 | A |
5697973 | Peyman et al. | Dec 1997 | A |
5702440 | Portney | Dec 1997 | A |
5708049 | Katagiri et al. | Jan 1998 | A |
5708064 | Coleman et al. | Jan 1998 | A |
5713844 | Peyman | Feb 1998 | A |
5713957 | Steele et al. | Feb 1998 | A |
5719656 | Bowling | Feb 1998 | A |
5720894 | Neev et al. | Feb 1998 | A |
5722971 | Peyman | Mar 1998 | A |
5725575 | O'Donnel, Jr. | Mar 1998 | A |
5731196 | Miller, III et al. | Mar 1998 | A |
5731862 | Winkler | Mar 1998 | A |
5733334 | Lee et al. | Mar 1998 | A |
5733760 | Lu et al. | Mar 1998 | A |
5746558 | Nygren et al. | May 1998 | A |
5752960 | Nallakrishnan | May 1998 | A |
5752967 | Kritzinger et al. | May 1998 | A |
5757458 | Miller et al. | May 1998 | A |
5766171 | Silvestrini | Jun 1998 | A |
5769889 | Kelman | Jun 1998 | A |
5771088 | Perrott | Jun 1998 | A |
5771742 | Bokaie et al. | Jun 1998 | A |
5774202 | Abraham et al. | Jun 1998 | A |
5782911 | Herrick | Jul 1998 | A |
5785651 | Kuhn et al. | Jul 1998 | A |
5786883 | Miller et al. | Jul 1998 | A |
5800533 | Eggleston et al. | Sep 1998 | A |
5806530 | Herrick | Sep 1998 | A |
5814680 | Imafuku et al. | Sep 1998 | A |
5824086 | Silvestrini | Oct 1998 | A |
5833701 | Gordon | Nov 1998 | A |
5836313 | Perez et al. | Nov 1998 | A |
5840848 | Sturrock et al. | Nov 1998 | A |
5843105 | Mathis et al. | Dec 1998 | A |
5843186 | Upsher | Dec 1998 | A |
5846256 | Mathis et al. | Dec 1998 | A |
5855605 | Herrick | Jan 1999 | A |
5858980 | Weiner et al. | Jan 1999 | A |
5861486 | DeVore et al. | Jan 1999 | A |
5863537 | Dalliet et al. | Jan 1999 | A |
5864128 | Plesko | Jan 1999 | A |
5864378 | Portney | Jan 1999 | A |
5865729 | Meehan et al. | Feb 1999 | A |
5870167 | Knopp et al. | Feb 1999 | A |
5874537 | Kelman et al. | Feb 1999 | A |
5876442 | Lipshitz et al. | Mar 1999 | A |
5888243 | Silverstrini | Mar 1999 | A |
5903099 | Johnson et al. | May 1999 | A |
5905561 | Lee et al. | May 1999 | A |
5919185 | Peyman | Jul 1999 | A |
5928283 | Gross et al. | Jul 1999 | A |
5929968 | Cotie et al. | Jul 1999 | A |
5935140 | Buratto | Aug 1999 | A |
5944752 | Silvestrini | Aug 1999 | A |
5960812 | Johnson | Oct 1999 | A |
5964748 | Peyman | Oct 1999 | A |
5964776 | Peyman | Oct 1999 | A |
5965330 | Evans et al. | Oct 1999 | A |
5968062 | Thomas et al. | Oct 1999 | A |
5980040 | Xu et al. | Nov 1999 | A |
5997559 | Ziemer | Dec 1999 | A |
6001386 | Ashton et al. | Dec 1999 | A |
6010510 | Brown et al. | Jan 2000 | A |
6010901 | Miller, III et al. | Jan 2000 | A |
6017121 | Chateau et al. | Jan 2000 | A |
6024447 | Portney | Feb 2000 | A |
6036957 | Weiner et al. | Mar 2000 | A |
D423669 | Huttner | Apr 2000 | S |
6050999 | Paraschac et al. | Apr 2000 | A |
6051023 | Kilmer et al. | Apr 2000 | A |
6063073 | Peyman | May 2000 | A |
6063118 | Nagamoto | May 2000 | A |
6066171 | Lipshitz et al. | May 2000 | A |
6068797 | Hunt | May 2000 | A |
6083236 | Feingold | Jul 2000 | A |
6086204 | Magnante | Jul 2000 | A |
6090141 | Lindstrom | Jul 2000 | A |
6096077 | Callahan et al. | Aug 2000 | A |
6102946 | Nigam | Aug 2000 | A |
6106552 | Lacombe et al. | Aug 2000 | A |
6110166 | Juhasz | Aug 2000 | A |
6125294 | Scholl et al. | Sep 2000 | A |
6126286 | Portney | Oct 2000 | A |
6138307 | McDonald | Oct 2000 | A |
6142999 | Brady et al. | Nov 2000 | A |
6143010 | Silvestrini | Nov 2000 | A |
6152959 | Portney | Nov 2000 | A |
6161544 | DeVore et al. | Dec 2000 | A |
6164282 | Gwon et al. | Dec 2000 | A |
6165189 | Ziemer | Dec 2000 | A |
6171336 | Sawusch | Jan 2001 | B1 |
6175754 | Scholl et al. | Jan 2001 | B1 |
6176878 | Gwon et al. | Jan 2001 | B1 |
6178593 | Carlson | Jan 2001 | B1 |
6183498 | DeVore et al. | Feb 2001 | B1 |
D439338 | Huttner | Mar 2001 | S |
6197019 | Peyman | Mar 2001 | B1 |
6197057 | Peyman et al. | Mar 2001 | B1 |
6197934 | DeVore et al. | Mar 2001 | B1 |
6203538 | Peyman | Mar 2001 | B1 |
6204365 | DeVore et al. | Mar 2001 | B1 |
6210005 | Portney | Apr 2001 | B1 |
6210401 | Lai | Apr 2001 | B1 |
6214044 | Silvestrini | Apr 2001 | B1 |
6217571 | Peyman | Apr 2001 | B1 |
6217596 | Farah | Apr 2001 | B1 |
6218360 | Cintron et al. | Apr 2001 | B1 |
6221067 | Peyman | Apr 2001 | B1 |
6221105 | Portney | Apr 2001 | B1 |
6228113 | Kauffman | May 2001 | B1 |
6228114 | Lee | May 2001 | B1 |
6228115 | Hoffmann et al. | May 2001 | B1 |
6231582 | Gandianco et al. | May 2001 | B1 |
6251118 | Proudfoot et al. | Jun 2001 | B1 |
6264648 | Peyman | Jul 2001 | B1 |
D447237 | Huttner et al. | Aug 2001 | S |
6277146 | Peyman et al. | Aug 2001 | B1 |
6280449 | Blake | Aug 2001 | B1 |
6280470 | Peyman | Aug 2001 | B1 |
6280471 | Peyman | Aug 2001 | B1 |
6283595 | Breger | Sep 2001 | B1 |
6302877 | Ruiz | Oct 2001 | B1 |
6308590 | Berto | Oct 2001 | B1 |
6312424 | Largent | Nov 2001 | B1 |
6316153 | Goodman et al. | Nov 2001 | B1 |
6335006 | Miller | Jan 2002 | B1 |
6352747 | Blackburn et al. | Mar 2002 | B1 |
6357875 | Herrick | Mar 2002 | B1 |
6358280 | Herrick | Mar 2002 | B1 |
6360883 | Haq et al. | Mar 2002 | B1 |
6361560 | Nigam | Mar 2002 | B1 |
6371973 | Tepper | Apr 2002 | B1 |
6376153 | Uchikawa et al. | Apr 2002 | B2 |
6387379 | Goldberg et al. | May 2002 | B1 |
6391055 | Ikada et al. | May 2002 | B1 |
6399734 | Hodd et al. | Jun 2002 | B1 |
6401916 | Sakanishi | Jun 2002 | B2 |
6403947 | Hoyt et al. | Jun 2002 | B1 |
6406494 | Laguette et al. | Jun 2002 | B1 |
6413276 | Werblin | Jul 2002 | B1 |
6416179 | Lieberman et al. | Jul 2002 | B1 |
6419697 | Kelman | Jul 2002 | B1 |
6423093 | Hicks et al. | Jul 2002 | B1 |
6425917 | Blake | Jul 2002 | B1 |
6432246 | Blake | Aug 2002 | B1 |
6436092 | Peyman | Aug 2002 | B1 |
6450642 | Jethmalani et al. | Sep 2002 | B1 |
6454800 | Dalton et al. | Sep 2002 | B2 |
6457826 | Lett | Oct 2002 | B1 |
6458141 | Peyman | Oct 2002 | B1 |
6470108 | Johnson | Oct 2002 | B1 |
6488707 | Callahan et al. | Dec 2002 | B1 |
6494910 | Ganem et al. | Dec 2002 | B1 |
6497700 | LaHaye | Dec 2002 | B1 |
6503276 | Lang et al. | Jan 2003 | B2 |
6515006 | Horn | Feb 2003 | B2 |
6520955 | Reynard | Feb 2003 | B2 |
6527389 | Portney | Mar 2003 | B2 |
6533905 | Johnson et al. | Mar 2003 | B2 |
6536899 | Fiala | Mar 2003 | B1 |
6551307 | Peyman | Apr 2003 | B2 |
6554424 | Miller et al. | Apr 2003 | B1 |
6554860 | Hoffmann et al. | Apr 2003 | B2 |
6555103 | Leukel et al. | Apr 2003 | B2 |
6569199 | Dotan et al. | May 2003 | B1 |
6575573 | Lai et al. | Jun 2003 | B2 |
6581993 | Nigam | Jun 2003 | B2 |
RE38193 | Bowling | Jul 2003 | E |
6588022 | Anders et al. | Jul 2003 | B1 |
6588902 | Isogai | Jul 2003 | B2 |
6589280 | Koziol | Jul 2003 | B1 |
6592621 | Domino | Jul 2003 | B1 |
6596026 | Gross et al. | Jul 2003 | B1 |
6599305 | Feingold | Jul 2003 | B1 |
6607527 | Ruiz et al. | Aug 2003 | B1 |
6607556 | Nigam | Aug 2003 | B1 |
6612907 | Ayyagari et al. | Sep 2003 | B2 |
6613088 | Babizhayev | Sep 2003 | B1 |
6614570 | Johnson et al. | Sep 2003 | B2 |
6620634 | Johnson et al. | Sep 2003 | B2 |
6622855 | Callahan et al. | Sep 2003 | B1 |
6623497 | Feingold | Sep 2003 | B1 |
6623522 | Nigam | Sep 2003 | B2 |
6624730 | Johnson et al. | Sep 2003 | B2 |
6626914 | Nigam | Sep 2003 | B2 |
6626941 | Nigam | Sep 2003 | B2 |
6632244 | Nigam | Oct 2003 | B1 |
6634931 | Ayyagari et al. | Oct 2003 | B2 |
6638304 | Azar | Oct 2003 | B2 |
6663668 | Chaouk et al. | Dec 2003 | B1 |
6669795 | Johnson et al. | Dec 2003 | B2 |
6673112 | Nigam | Jan 2004 | B2 |
6692126 | Xie et al. | Feb 2004 | B1 |
6702807 | Peyman | Mar 2004 | B2 |
6729599 | Johnson | May 2004 | B2 |
6729939 | Wrue | May 2004 | B2 |
6740116 | Morcher | May 2004 | B2 |
6742761 | Johnson et al. | Jun 2004 | B2 |
6746890 | Gupta et al. | Jun 2004 | B2 |
6749632 | Jethmalani et al. | Jun 2004 | B2 |
6755819 | Waelti | Jun 2004 | B1 |
6755858 | White | Jun 2004 | B1 |
D493889 | Yoo | Aug 2004 | S |
6786911 | Mitomo et al. | Sep 2004 | B2 |
6786926 | Peyman | Sep 2004 | B2 |
6790298 | Johnson et al. | Sep 2004 | B2 |
6811256 | Becherer et al. | Nov 2004 | B1 |
6813097 | Jethmalani et al. | Nov 2004 | B2 |
6824266 | Jethmalani et al. | Nov 2004 | B2 |
6849090 | Nigam | Feb 2005 | B2 |
6851804 | Jethmalani et al. | Feb 2005 | B2 |
6855163 | Peyman | Feb 2005 | B2 |
6866563 | Green | Mar 2005 | B2 |
6874886 | Miller et al. | Apr 2005 | B2 |
6899424 | Miller et al. | May 2005 | B2 |
6908363 | Green | Jun 2005 | B2 |
6949093 | Peyman | Sep 2005 | B1 |
6951556 | Epstein | Oct 2005 | B2 |
6966648 | Miller et al. | Nov 2005 | B2 |
6976584 | Maiola et al. | Dec 2005 | B2 |
6976997 | Noolandi et al. | Dec 2005 | B2 |
6986763 | Holmen | Jan 2006 | B2 |
6989008 | Peyman | Jan 2006 | B2 |
7001374 | Peyman | Feb 2006 | B2 |
7008447 | Koziol | Mar 2006 | B2 |
7025455 | Roffman | Apr 2006 | B2 |
7037338 | Nagamoto | May 2006 | B2 |
7097549 | Allison et al. | Aug 2006 | B2 |
7097649 | Meyer | Aug 2006 | B2 |
7101043 | Kumar et al. | Sep 2006 | B2 |
7166357 | Kumar et al. | Jan 2007 | B2 |
7179292 | Worst et al. | Feb 2007 | B2 |
7189456 | King | Mar 2007 | B2 |
7207998 | Feingold | Apr 2007 | B2 |
7258437 | King et al. | Aug 2007 | B2 |
7261843 | Knox et al. | Aug 2007 | B2 |
7281699 | Hovey et al. | Oct 2007 | B2 |
7320826 | Kumar et al. | Jan 2008 | B2 |
7364674 | Hoover | Apr 2008 | B1 |
D569512 | Poll et al. | May 2008 | S |
D571915 | Poll et al. | Jun 2008 | S |
7399811 | Mentak et al. | Jul 2008 | B2 |
7404637 | Miller et al. | Jul 2008 | B2 |
7404638 | Miller et al. | Jul 2008 | B2 |
7446157 | Mentak et al. | Nov 2008 | B2 |
7452074 | Kumar et al. | Nov 2008 | B2 |
7462194 | Blake | Dec 2008 | B1 |
7465414 | Knox et al. | Dec 2008 | B2 |
7491350 | Silvestrini | Feb 2009 | B2 |
D589615 | Doenges | Mar 2009 | S |
7560056 | Van Gemert et al. | Jul 2009 | B2 |
7584630 | Van Gemert | Sep 2009 | B2 |
7628810 | Christie et al. | Dec 2009 | B2 |
7645291 | Ross et al. | Jan 2010 | B2 |
7645299 | Koziol | Jan 2010 | B2 |
7666331 | King et al. | Feb 2010 | B2 |
7674288 | Nagamoto | Mar 2010 | B2 |
7745555 | Mentak et al. | Jun 2010 | B2 |
7757629 | Lydon et al. | Jul 2010 | B2 |
7811480 | King et al. | Oct 2010 | B2 |
7815678 | Ben Nun | Oct 2010 | B2 |
7828844 | Marmo et al. | Nov 2010 | B2 |
7847998 | Kumar et al. | Dec 2010 | B2 |
7856939 | Minor et al. | Dec 2010 | B2 |
7906214 | Seybert et al. | Mar 2011 | B2 |
7976577 | Silvestrini | Jul 2011 | B2 |
7992906 | Nigam | Aug 2011 | B2 |
D645337 | Hsu et al. | Sep 2011 | S |
8048972 | Mentak et al. | Nov 2011 | B2 |
8079706 | Silvestrini et al. | Dec 2011 | B2 |
D656256 | Christie et al. | Mar 2012 | S |
8216765 | Morimitsu et al. | Jul 2012 | B2 |
8287592 | Silvestrini | Oct 2012 | B2 |
8343215 | Miller et al. | Jan 2013 | B2 |
8349006 | Zhao et al. | Jan 2013 | B2 |
D681086 | Christie et al. | Apr 2013 | S |
8420753 | Mentak et al. | Apr 2013 | B2 |
8460374 | Christie et al. | Jun 2013 | B2 |
8547625 | Knowles et al. | Oct 2013 | B2 |
8568478 | Zickler et al. | Oct 2013 | B2 |
8604098 | Boydston et al. | Dec 2013 | B2 |
8633292 | Hu et al. | Jan 2014 | B2 |
8649081 | DeMeio et al. | Feb 2014 | B1 |
8740978 | Weeber et al. | Jun 2014 | B2 |
8752958 | Miller et al. | Jun 2014 | B2 |
8828284 | Carpenter | Sep 2014 | B2 |
8857803 | Schaper, Jr. et al. | Oct 2014 | B2 |
9030740 | DeMeio et al. | May 2015 | B2 |
9204962 | Silvestrini | Dec 2015 | B2 |
9220590 | Beer | Dec 2015 | B2 |
9304330 | Park et al. | Apr 2016 | B2 |
9603704 | Silvestrini | Mar 2017 | B2 |
9693858 | Hildebrand et al. | Jul 2017 | B2 |
9737461 | Feingold | Aug 2017 | B2 |
10350058 | Silvestrini | Jul 2019 | B2 |
10619018 | Kumar et al. | Apr 2020 | B2 |
10939995 | Silvestrini | Mar 2021 | B2 |
20010004702 | Peyman | Jun 2001 | A1 |
20010027314 | Peyman | Oct 2001 | A1 |
20010034516 | Peyman | Oct 2001 | A1 |
20010047203 | Dalton et al. | Nov 2001 | A1 |
20010050750 | Breger | Dec 2001 | A1 |
20020010510 | Silverstrini | Jan 2002 | A1 |
20020016629 | Sandstedt et al. | Feb 2002 | A1 |
20020028330 | Patel et al. | Mar 2002 | A1 |
20020029981 | Nigam | Mar 2002 | A1 |
20020042004 | Sandstedt et al. | Apr 2002 | A1 |
20020055753 | Silvestrini | May 2002 | A1 |
20020057148 | Johnson et al. | May 2002 | A1 |
20020075447 | Andino et al. | Jun 2002 | A1 |
20020082288 | Horn | Jun 2002 | A1 |
20020107337 | Rosenzweig et al. | Aug 2002 | A1 |
20020107566 | Nigam | Aug 2002 | A1 |
20020111677 | Nigam | Aug 2002 | A1 |
20020120329 | Lang et al. | Aug 2002 | A1 |
20020128710 | Eggleston | Sep 2002 | A1 |
20020133228 | Sarver | Sep 2002 | A1 |
20020138070 | Peyman | Sep 2002 | A1 |
20020167640 | Francis et al. | Nov 2002 | A1 |
20020167735 | Jethmalani et al. | Nov 2002 | A1 |
20020169491 | Foster et al. | Nov 2002 | A1 |
20020169505 | Jethmalani et al. | Nov 2002 | A1 |
20020173846 | Blake et al. | Nov 2002 | A1 |
20020187986 | Horn | Dec 2002 | A1 |
20020188351 | Laguette | Dec 2002 | A1 |
20020193052 | Ayyagari et al. | Dec 2002 | A1 |
20020196409 | Jani | Dec 2002 | A1 |
20030002994 | Johnson et al. | Jan 2003 | A1 |
20030007122 | Streibig | Jan 2003 | A1 |
20030014021 | Holmen | Jan 2003 | A1 |
20030014042 | Juhasz et al. | Jan 2003 | A1 |
20030014107 | Reynard | Jan 2003 | A1 |
20030033013 | Callahan et al. | Feb 2003 | A1 |
20030045930 | Nguyen | Mar 2003 | A1 |
20030048411 | Jethmalani et al. | Mar 2003 | A1 |
20030055497 | Hicks et al. | Mar 2003 | A1 |
20030071893 | Miller et al. | Apr 2003 | A1 |
20030078655 | Callahan et al. | Apr 2003 | A1 |
20030088313 | Nigam | May 2003 | A1 |
20030090013 | Jethmalani et al. | May 2003 | A1 |
20030090624 | Jethmalani et al. | May 2003 | A1 |
20030093083 | Peyman | May 2003 | A1 |
20030093150 | Jethmalani et al. | May 2003 | A1 |
20030105521 | Perez | Jun 2003 | A1 |
20030115718 | Bechthold | Jun 2003 | A1 |
20030127318 | Johnson et al. | Jul 2003 | A1 |
20030128336 | Jethmalani et al. | Jul 2003 | A1 |
20030151825 | Bielawski et al. | Aug 2003 | A1 |
20030151831 | Sandstedt et al. | Aug 2003 | A1 |
20030174375 | Jethmalani et al. | Sep 2003 | A1 |
20030176521 | Jethmalani et al. | Sep 2003 | A1 |
20030216763 | Patel | Nov 2003 | A1 |
20030220653 | Perez | Nov 2003 | A1 |
20040014253 | Gupta et al. | Jan 2004 | A1 |
20040015234 | Peyman | Jan 2004 | A1 |
20040019379 | Glick et al. | Jan 2004 | A1 |
20040047014 | Parker et al. | Mar 2004 | A1 |
20040049174 | Peyman | Mar 2004 | A1 |
20040056371 | Liao et al. | Mar 2004 | A1 |
20040068317 | Knight | Apr 2004 | A1 |
20040078075 | Koziol | Apr 2004 | A1 |
20040080239 | Gupta et al. | Apr 2004 | A1 |
20040086479 | Grinstaff et al. | May 2004 | A1 |
20040105971 | Parrinello et al. | Jun 2004 | A1 |
20040106929 | Masket | Jun 2004 | A1 |
20040127911 | Figueroa et al. | Jul 2004 | A1 |
20040220666 | Cumming | Nov 2004 | A1 |
20040243231 | Koziol | Dec 2004 | A1 |
20050027354 | Brady et al. | Feb 2005 | A1 |
20050027355 | Murakami | Feb 2005 | A1 |
20050031697 | Vehige et al. | Feb 2005 | A1 |
20050033420 | Christie et al. | Feb 2005 | A1 |
20050046794 | Silvestrini et al. | Mar 2005 | A1 |
20050049621 | Feingold et al. | Mar 2005 | A1 |
20050080485 | Nigam | Apr 2005 | A1 |
20050090895 | Peyman | Apr 2005 | A1 |
20050099597 | Sandstedt et al. | May 2005 | A1 |
20050119738 | Nigam | Jun 2005 | A1 |
20050124983 | Fret et al. | Jun 2005 | A1 |
20050126948 | Maiola et al. | Jun 2005 | A1 |
20050143717 | Peyman | Jun 2005 | A1 |
20050143812 | Paul et al. | Jun 2005 | A1 |
20050182488 | Peyman | Aug 2005 | A1 |
20050187621 | Brady | Aug 2005 | A1 |
20050196626 | Knox et al. | Sep 2005 | A1 |
20050222679 | Peyman | Oct 2005 | A1 |
20050228376 | Boomer et al. | Oct 2005 | A1 |
20050246015 | Miller | Nov 2005 | A1 |
20050246016 | Miller et al. | Nov 2005 | A1 |
20050246019 | Blake et al. | Nov 2005 | A1 |
20060037871 | Jin et al. | Feb 2006 | A1 |
20060064077 | Peyman | Mar 2006 | A1 |
20060079959 | Christie et al. | Apr 2006 | A1 |
20060079960 | Christie et al. | Apr 2006 | A1 |
20060095127 | Feingold et al. | May 2006 | A1 |
20060098162 | Bandhauer et al. | May 2006 | A1 |
20060113054 | Silvestrini | Jun 2006 | A1 |
20060117919 | Stute | Jun 2006 | A1 |
20060118263 | Silvestrini | Jun 2006 | A1 |
20060184243 | Yilmaz | Aug 2006 | A1 |
20060203192 | Miller et al. | Sep 2006 | A1 |
20060228560 | Stewart et al. | Oct 2006 | A1 |
20060235428 | Silvestrini | Oct 2006 | A1 |
20060241751 | Marmo et al. | Oct 2006 | A1 |
20060252844 | Mentak | Nov 2006 | A1 |
20060265058 | Silvestrini | Nov 2006 | A1 |
20060268226 | Christie et al. | Nov 2006 | A1 |
20060268227 | Christie et al. | Nov 2006 | A1 |
20060268228 | Christie et al. | Nov 2006 | A1 |
20060268229 | Silvestrini et al. | Nov 2006 | A1 |
20060270946 | Silvestrini et al. | Nov 2006 | A1 |
20060271026 | Silvestrini et al. | Nov 2006 | A1 |
20060271027 | Silvestrini et al. | Nov 2006 | A1 |
20060271176 | Christie et al. | Nov 2006 | A1 |
20060271177 | Christie et al. | Nov 2006 | A1 |
20060271178 | Christie et al. | Nov 2006 | A1 |
20060271179 | Christie et al. | Nov 2006 | A1 |
20060271180 | Christie et al. | Nov 2006 | A1 |
20060271181 | Christie et al. | Nov 2006 | A1 |
20060271182 | Christie et al. | Nov 2006 | A1 |
20060271183 | Christie et al. | Nov 2006 | A1 |
20060271184 | Silvestrini | Nov 2006 | A1 |
20060271185 | Silvestrini | Nov 2006 | A1 |
20060274264 | Christie et al. | Dec 2006 | A1 |
20060274265 | Christie et al. | Dec 2006 | A1 |
20070016234 | Daxer | Jan 2007 | A1 |
20070129797 | Lang et al. | Jun 2007 | A1 |
20070177100 | Knox | Aug 2007 | A1 |
20070219542 | Yahagi | Sep 2007 | A1 |
20070225691 | Silvestrini et al. | Sep 2007 | A1 |
20070260308 | Tran | Nov 2007 | A1 |
20080033546 | Liang | Feb 2008 | A1 |
20080051801 | Hovey et al. | Feb 2008 | A1 |
20080077238 | Deacon et al. | Mar 2008 | A1 |
20080125862 | Blake | May 2008 | A1 |
20080151183 | Altmann | Jun 2008 | A1 |
20080187749 | Cael et al. | Aug 2008 | A1 |
20080212030 | Bentley et al. | Sep 2008 | A1 |
20080275462 | Feingold | Nov 2008 | A1 |
20080288066 | Cumming | Nov 2008 | A1 |
20090012505 | Chernyak | Jan 2009 | A1 |
20090059168 | Miller et al. | Mar 2009 | A1 |
20090069817 | Peyman | Mar 2009 | A1 |
20090204207 | Blum et al. | Aug 2009 | A1 |
20090222086 | Lui et al. | Sep 2009 | A1 |
20090287306 | Smith et al. | Nov 2009 | A1 |
20090306773 | Silvestrini et al. | Dec 2009 | A1 |
20100149618 | Sprague | Jun 2010 | A1 |
20100232003 | Baldy et al. | Sep 2010 | A1 |
20100234942 | Peyman | Sep 2010 | A1 |
20100312336 | Hong et al. | Dec 2010 | A1 |
20110172675 | Danta et al. | Jan 2011 | A1 |
20110040376 | Christie et al. | Feb 2011 | A1 |
20110245818 | Weinschenk, III | Oct 2011 | A1 |
20110245919 | Pettit | Oct 2011 | A1 |
20120109294 | Olson | May 2012 | A1 |
20120143325 | Christie et al. | Jun 2012 | A1 |
20120203239 | Vukich et al. | Aug 2012 | A1 |
20120245683 | Christie et al. | Sep 2012 | A1 |
20120309761 | Chow et al. | Dec 2012 | A1 |
20120310338 | Christie et al. | Dec 2012 | A1 |
20130053953 | Silvestrini | Feb 2013 | A1 |
20130103147 | Christie et al. | Apr 2013 | A1 |
20130131795 | Miller et al. | May 2013 | A1 |
20130238091 | Danta et al. | Sep 2013 | A1 |
20130268071 | Vilupuru et al. | Oct 2013 | A1 |
20140131905 | Webb | May 2014 | A1 |
20140264979 | Park et al. | Sep 2014 | A1 |
20140265010 | Park et al. | Sep 2014 | A1 |
Number | Date | Country |
---|---|---|
241 330 | Dec 1992 | AR |
241 830 | Dec 1992 | AR |
244 890 | Nov 1993 | AR |
739297 | Jan 2002 | AU |
0772492 | Aug 2004 | AU |
778310 | Mar 2005 | AU |
2003252004 | Mar 2010 | AU |
2009200310 | Feb 2011 | AU |
2010201777 | May 2011 | AU |
2006236715 | Jun 2012 | AU |
0008601 | Dec 2001 | BR |
0008624 | Dec 2001 | BR |
PI-9809289-8 | Dec 2006 | BR |
2286718 | Nov 2008 | CA |
1253484 | May 2000 | CN |
1875895 | Dec 2006 | CN |
101198294 | Jun 2008 | CN |
101198364 | Jun 2008 | CN |
101322663 | Dec 2008 | CN |
102448404 | May 2012 | CN |
102470033 | May 2012 | CN |
101930093 | Aug 2015 | CN |
3433581 | Mar 1986 | DE |
41 34 320 | Apr 1992 | DE |
0165652 | Dec 1985 | EP |
0225098 | Jun 1987 | EP |
0286433 | Oct 1988 | EP |
0443094 | Aug 1991 | EP |
0457553 | Nov 1991 | EP |
0941717 | Sep 1999 | EP |
1014872 | Jul 2000 | EP |
1173790 | Jan 2002 | EP |
1267998 | Jan 2003 | EP |
1381326 | Jan 2004 | EP |
1871298 | Apr 2006 | EP |
1159033 | Jan 2007 | EP |
1827330 | Sep 2007 | EP |
1845896 | Oct 2007 | EP |
1890736 | Feb 2008 | EP |
1917932 | May 2008 | EP |
1158936 | Jul 2008 | EP |
1997530 | Dec 2008 | EP |
1534188 | Sep 2010 | EP |
2258311 | Dec 2010 | EP |
2301477 | Mar 2011 | EP |
1635739 | Sep 2011 | EP |
2464310 | Jun 2012 | EP |
2464311 | Jun 2012 | EP |
2506803 | Oct 2012 | EP |
1515699 | Jun 2013 | EP |
2967839 | Jan 2016 | EP |
369 993 | Jan 1907 | FR |
1115140 | Dec 1955 | FR |
1400566 | Apr 1965 | FR |
2599156 | May 1986 | FR |
2620687 | Mar 1989 | FR |
2649605 | Jan 1991 | FR |
2790944 | Sep 2000 | FR |
1 026 839 | Apr 1966 | GB |
1276003 | Jun 1972 | GB |
1 547 525 | Jun 1979 | GB |
2242835 | Oct 1991 | GB |
1028531 | Feb 2011 | HK |
1151451 | Feb 2012 | HK |
11553484 | May 2012 | HK |
1166457 | Nov 2012 | HK |
1169935 | Feb 2013 | HK |
62167343 | Jul 1987 | JP |
63-17096 | Apr 1988 | JP |
64-002644 | Jan 1989 | JP |
1990-7954 | Jan 1990 | JP |
03-001857 | Jan 1991 | JP |
04-158859 | Jun 1992 | JP |
04-223425 | Aug 1992 | JP |
06-509731 | Mar 1993 | JP |
H05-65340 | Sep 1993 | JP |
6-502782 | Mar 1994 | JP |
6-509731 | Nov 1994 | JP |
07-050242 | Feb 1995 | JP |
07-178125 | Jul 1995 | JP |
07-265340 | Oct 1995 | JP |
08-103457 | Apr 1996 | JP |
09-502542 | Mar 1997 | JP |
11-503657 | Aug 1997 | JP |
2002-14772 | Jan 2002 | JP |
2003-527228 | Sep 2003 | JP |
2004-510199 | Apr 2004 | JP |
2004-538034 | Dec 2004 | JP |
2005-533576 | Nov 2005 | JP |
2007-516019 | Jun 2007 | JP |
2007-523720 | Aug 2007 | JP |
4114036 | Apr 2008 | JP |
2008-517671 | May 2008 | JP |
2008-536574 | Sep 2008 | JP |
2008-536576 | Sep 2008 | JP |
4182390 | Sep 2008 | JP |
2010-227615 | Oct 2010 | JP |
2010-126600 | Feb 2011 | JP |
4676761 | Feb 2011 | JP |
4689615 | Feb 2011 | JP |
4746052 | May 2011 | JP |
10-0335722 | May 2002 | KR |
600210 | Jul 2006 | KR |
1008759 | Jul 2003 | MX |
226369 | Feb 2005 | MX |
227913 | Mar 2006 | MX |
562987 | Feb 2010 | NZ |
2138837 | Sep 1999 | RU |
68726 | Feb 2002 | SG |
83306 | Feb 2004 | SG |
83307 | Jul 2004 | SG |
200716909-7 | Mar 2011 | SG |
1380743 | Mar 1998 | SU |
WO 8705797 | Oct 1987 | WO |
WO 8707165 | Dec 1987 | WO |
WO 9116865 | Nov 1991 | WO |
WO 9205694 | Apr 1992 | WO |
WO 9303776 | Mar 1993 | WO |
WO 9308878 | May 1993 | WO |
WO 9312735 | Jul 1993 | WO |
WO 9320763 | Oct 1993 | WO |
WO 9401058 | Jan 1994 | WO |
WO 9405232 | Mar 1994 | WO |
WO 9423327 | Oct 1994 | WO |
WO 9502356 | Jan 1995 | WO |
WO 9503747 | Feb 1995 | WO |
WO 9508135 | Mar 1995 | WO |
WO 9635397 | Nov 1996 | WO |
WO 9728759 | Aug 1997 | WO |
WO 9748004 | Dec 1997 | WO |
WO 9748005 | Dec 1997 | WO |
WO 9827896 | Jul 1998 | WO |
WO 9848715 | Nov 1998 | WO |
WO 9907309 | Feb 1999 | WO |
WO 0025704 | May 2000 | WO |
WO 0038594 | Jul 2000 | WO |
WO 0051682 | Sep 2000 | WO |
WO 0052516 | Sep 2000 | WO |
WO 0110641 | Feb 2001 | WO |
WO 0115779 | Mar 2001 | WO |
WO 0117460 | Mar 2001 | WO |
WO 0119364 | Mar 2001 | WO |
WO 0182815 | Nov 2001 | WO |
WO 0187189 | Nov 2001 | WO |
WO 0213881 | Feb 2002 | WO |
WO 02016077 | Feb 2002 | WO |
WO 020027388 | Apr 2002 | WO |
WO 02076320 | Oct 2002 | WO |
WO 02102241 | Dec 2002 | WO |
WO 03001555 | Jan 2003 | WO |
WO 03020177 | Mar 2003 | WO |
WO 03022168 | Mar 2003 | WO |
WO 03030763 | Apr 2003 | WO |
WO 03061518 | Jul 2003 | WO |
WO 2004014969 | Feb 2004 | WO |
WO 2004034917 | Apr 2004 | WO |
WO 2004050132 | Jun 2004 | WO |
WO 04105588 | Dec 2004 | WO |
WO 2004105588 | Dec 2004 | WO |
WO 2005033263 | Apr 2005 | WO |
WO 2005082265 | Sep 2005 | WO |
WO 2006020638 | Feb 2006 | WO |
WO 06047698 | May 2006 | WO |
WO 2006047534 | May 2006 | WO |
WO 2006060380 | Jun 2006 | WO |
WO 2006113377 | Oct 2006 | WO |
WO 2006113411 | Oct 2006 | WO |
WO 2006113474 | Oct 2006 | WO |
WO 2006113563 | Oct 2006 | WO |
WO 2006113564 | Oct 2006 | WO |
WO 07057734 | May 2007 | WO |
WO 2007057734 | Oct 2007 | WO |
WO 2007142981 | Dec 2007 | WO |
WO 2008036671 | Mar 2008 | WO |
WO 2008102096 | Aug 2008 | WO |
WO 2008121649 | Oct 2008 | WO |
WO 2009050511 | Apr 2009 | WO |
WO 2009122409 | Oct 2009 | WO |
WO 2009149060 | Dec 2009 | WO |
WO 2011020074 | Feb 2011 | WO |
WO 2011020078 | Feb 2011 | WO |
WO 2011047076 | Apr 2011 | WO |
WO 2011069059 | Jun 2011 | WO |
WO 2011088107 | Jul 2011 | WO |
WO 2012170066 | Dec 2012 | WO |
WO 2013082545 | Jun 2013 | WO |
WO 2013123265 | Aug 2013 | WO |
WO 2014074610 | May 2014 | WO |
WO 2014158653 | Oct 2014 | WO |
Entry |
---|
Accomodation and acuity under night-driving illumination levels. Arumi et al. Ophthal. Physiol. Opt. vol 17, No. 4, pp. 291-299,1997. |
Accommodation and Presbyopia. Croft et al., International Opthalmology Clinics: Spring 2001, vol. 41, Issue 2, pp. 33-46. |
Accomodation dynamics as a function of age. Heron et al. Ophthal. Physiol. Opt. 2002 22:389-396. |
Accommodation Responses and Ageing. Heron et al. IOVS, Nov. 1999, vol. 40, No. 12, pp. 2872-2883. |
Accommodative responses to anisoaccommodative targets. Koh et al. Ophthal. Physiol. Opt. vol. 18, No. 3, pp. 254-262, 1998. |
Accommodation responses to flickering stimuli. Chauhan et al. Ophthal. Physiol. Opt. vol. 16. No. 5, pp. 391-408, 1996. |
Accommodation to perceived depth in stereo tests. Koh et al. Ophthal. Physiol. Opt. vol. 18, No. 3, pp. 279-284, 1998. |
Age Changes in the Interactions between the Accommodation and Vergence Systems. Heron et al. Optometry and Vision Science. vol. 78, No. 10, Oct. 2001. |
Anterior Ciliary Sclerotomy for Treatment of Presbyopia: A Prospective Controlled Study. Hamilton et al. Ophthalmology, vol. 109, No. 11: Nov. 2002: pp. 1970-1977. |
Barraquer, “Keratomileusis for Myopia and Aphakia”, Ophthalmology, Rochester 88:701-708, 1981. |
Binder et al., “Hydrogel keratophakia in non-human primates”, Current Eye Research, vol. 1, No. 9, 1981/1982, pp. 535-542. |
Brooks, J. et al., Identification of a vimentin-reactive Peptide associated with ocular lens membranes as cytokeratin, Ophthalmic Res., Jan.-Feb. 2003, pp. 8-11, vol. 35. |
Cao et al., “Comparative study of the use of poly(glycolic acid), calcium alginate and pluronics in the engineering of autologous porcine cartilage”, Polymers for Tissue Engineering, pp. 315-327, VSP 1998. |
Can Accommodation be Surgically Restored in Human Presbyopia? Glasser, Adrian. Optometry and Vision Science, vol. 76, No. 9, Sep. 1999. |
Changes in the static accommodation response with age. Kalsi et al. Ophthal. Physiol. Opt. vol. 21, No. 1, pp. 77-84, 2001. |
Choice of Spatial Frequency for Contrast Sensitivity Evaluation After Corneal Refractive Surgery. Montes-Mico et al. Journal of Refractive Surgery, vol. 17: Nov./Dec. 2001: pp. 646-651. |
Chow, C., et al., Broadband optical ultrasound sensor with a unique open-cavity structure, J. Biomed. Opt., Jan.-Feb. 2011, pp. 017001, vol. 16. |
Choyce, P. “Implants with Coloured and Opaque Portions: Implants with Built-In Stenopeic Aperture,” pp. 21-26 |
“Uniocular Aphakia Corrected by Anterior Chamber Implants with Built-In Stenopeic Aperture,” pp. 132-136, 1964. |
Clinical Characteristics of Lamellar Channel Deposits After Implementation of Intacs. Ruckhofer et al. J Cataract Refract Surg, vol. 26, Oct. 2000: pp. 1473-1479. |
Contemporary Polymer Applications for Corneal Surgery. McCarey, Bernard E. pp. 504-505. |
Cotliar et al., “Excimer Laser Radial Keratotomy”, Ophthalmology, 1985. |
Corneal Topography: The State of the Art, Alignment of Videokeratographs. Mandell et al. Chpt. 2, pp. 17-23, Jan. 1995. |
“Corneal Surgery” by L. Girard, The C.V. Mosby Publishing Company, London 1981 pp. 107-141. |
Dynamics of the accommodation response to abrupt changes in target vergence as a function of age. Heron et al. Vision Research 41 (2001) 507-519. |
Dynamic retinoscopy and accomodation. Whitefoot et al. Ophthal. Physiol. Opt. vol. 12, Jan. 1992, pp. 8-17. |
Eduard Jaeger's Test-Types (Schrift-Scalen) and Historical Development of Vision Tests. Runge, Paul E. Tr. Am. Ophth. Soc. vol. 98, 2000: 375. |
Eight Years Experience with Permalens Intracorneal Lenses in Nonhuman Primates. Werblin et al. |
Refractive & Corneal Surgery, vol. 8, Jan./Feb. 1992, pp. 12-21. |
“Epikeratophakia: Techniques, Compositions, and Clinical Results” by Werblin, Ophthalmology, 1983, pp. 45-58. |
Errors in determining the direction of the visual axis in the presence of defocus. Atchison et al. |
Ophthal. Physiol. Opt., vol. 18, No. 5, pp. 463-467,1998. |
Evaluate surgical routine to determine DLK cause, surgeon advises. Piechocki, Michael. Ocular Surgery News: Refractive Surgery, Jan. 1, 2003: p. 14. |
Explanation for the observation of isogyres in crystalline lenses viewed between crossed polarizers. Ophthal. Physiol. Opt., vol. 13, Apr. 1993, pp. 209-211. |
FDA Summary of Safety and Effectiveness Data for Tecnis Multifocal Posterior Chamber Intraocular Lens, Models ZM900 and ZMA00, 2009. |
FDA Summary of Safety and Effectiveness Data for the Advanced Vision Science, Inc. XACT Foldable Hydrophopic Acrylic Ultraviolet Light-Absorving Posterior Chamber Intraocular Lens (Model X-60 and Model X-70), 2009. |
FDA Summary of Safety and Effectiveness Data for EC-3 IOL, (Models EC-3 IOL and EC-3 Precision Aspheric Lens), 2010. |
FDA Summary of Safety and Effectiveness Data for Aaren Scientific's EC-3 IOL, 2010. |
FDA Summary of Safety and Effectiveness Data for XACT Foldable Hydrophopic Acrylic UV Absorving Posterior Chamber Intraocular Lens discussing clinical investigation beginning on May 8, 2002. |
Flap Measurements With the Hansatome Microkeratome. Spadea et al. Journal of Refractive Surgery, vol. 18, Mar./Apr. 2002: pp. 149-154. |
Focused and divided attention in stereoscopic depth. Wickens et al. SPIE, vol. 1256 Stereoscopic Displays and Applications (1990); pp. 28-34. |
Gamez, G., et al., Development of a pulsed radio frequency glow discharge for three-dimensional elemental surface imaging. 1. Application to biopolymer analysis, Anal. Chem., Feb. 2007, pp. 1317-1326, vol. 79. |
Glasier, M., et al., A solid-phase assay for the quantitation of total protein eluted from balafilcon, lotrafilcon, and etafilcon contact lenses, Current Eye Research, 2008, pp. 631-640, vol. 33. |
Griffith et al.; “Functional Human Corneal Equivalents Constructed from Cell Lines”, Science, vol. 286, Dec. 10, 1999 pp. 2169-2172. |
Groppi, J. J. “New Aspects in the Fitting of the Multi-Range Bifocal Contact Lens” Contacto, vol. 15:22-29 1971. |
Guyton A.C., Textbook of Medical Physiology, 7th Edition, W.B. Saunders Company, 1986: Chapter 58, pp. 700-710. |
Hara, T., et al., Accommodative intraocular lens with spring action. Part 1. Design and placement in an excised animal eye, Ophthalmic Surg., Feb. 1990, vol. 21. |
Hara, T., et al., Ten-year results of anterior chamber fixation of the posterior chamber intraocular lens, Arch. Ophthalmol., Aug. 2004, pp. 1112-1116. |
Hayasaka, S., et al., Scanning electron microscopic study of polyvinylidene fluoride degradation by ocular tissue extracts, Jpn. J. Ophthalmol., 1984, pp. 131-135, vol. 28. |
Hayashi, K., et al., Intraocular lens factors that may affect anterior capsule contraction, Ophthalmology, Feb. 2005, pp. 286-292, vol. 112. |
Hayashi, K., et al., Comparison of decentration and tilt between one piece and three piece polymethyl methacrylate intraocular lenses, Br. J. Ophthalmol., Apr. 1998, pp. 419-422, vol. 82. |
Hidaka, T. et al, Adaptive optics instrumentation in submillimeter/terahertz spectroscopy with a flexible polyvinylidene fluoride cladding hollow waveguide, Rev. Sci. Instrum., 2007, pp. 25-26, vol. 78. |
Hoffer et al., “UCLA Clinical Trial of Radial Keratotomy” Opthalmology, Aug. 1981; 88:729-736. |
Holes in Clear Lenses Demonstrate a Pinhole Effect. Zacharia et al. Arch Ophthalmol, vol. 106, Apr. 1988, pp. 511-513. |
Human Visual System—Image Formation, Encyclopedia of Imaging Science and Technology, Roorda, A., 2002, pp. 539-557. |
Hybrid diffractive-refractive achromatic spectacle lenses. Charman, W. N. Ophthal. Physiol. Opt., vol. 14, Oct. 1994: pp. 389-392. |
Iijima et al. “Formation of a spherical multicellular aggregate (spheroid) of animal cells in the pores of polyurethane foam as a cell culture substratum and its application to a hybrid artificial liver”, Polymers for Tissue Engineering , pp. 273-286, VSP 1998. |
Imaging in the 21st century. Charman, W. N. Ophthal. Physiol. Opt., vol. 18, No. 2, pp. 210-223,1998. |
International Preliminary Report on Patentability for PCT/US2014/020252 dated Sep. 15, 2015 in 10 pages. |
International Search Report and Written Opinion for PCT/US2014/020252 dated Jul. 7, 2014 in 16 pages. |
Intra-Ocular Lenses and Implants. Choyce, Peter. Chpts.4 & 17, 1964. |
Intraocular pressure after excimer laser myopic refractive surgery. Montes-Mico et al. Ophthal. Physiol. Opt., vol. 21, No. 3, pp. 228-235, 2001. |
Intrastromal Crystalline Deposits Following Hydrogel Keratophakia in Monkeys. Parks et al. Cornea, 12(1): 29-34,1993. |
Izak, A., et al., Loop memory of haptic materials in posterior chamber intraocular lenses, J. Cataract Refract. Surg., Jul. 2002, pp. 1129-1135, vol. 28. |
“Katena Eye Instruments Catalog—Blaydes” dated Feb. 22, 2010, obtained from the Internet at: www.katena.com/html/product_detail.cfm in 1 page and printed on Feb. 22, 2010. |
Kenyon. “Recurrent Corneal Erosion: Pathogenesis and Therapy,” 1978, pp. 169-195. |
“Keratomileusis and Keratophakia in the Surgical Correction of Aphakia” by Barraquer, Cataract Surgery and Special Techniques, prior to 1996 pp. 270-289. |
Khodadoust et al., “Adhesion of Regenerating Corneal Epithelium,” Am. J. of Opthalmology, Mar. 1968, pp. 339-348. |
Kimura, W., et al., Comparison of shape recovery ratios in various IOL haptics, Nippon Ganka Gakkai Zasshi, Jun. 1991, pp. 548-555, vol. 95. |
Kimura, W., et al., Comparison of shape recovery ratios in various intraocular lens haptics, J. Cataract. Refract. Surg., Nov. 1992, pp. 547-553, vol. 18. |
Kimura, W., et al., Comparison of shape recovery ratios of single-piece poly(methyl methacrylate) intraocular lens haptics., J. Cataract. Refract. Surg., Sep. 1993, pp. 635-639, vol. 19. |
Ko, A. et al. Seroreactivity against aqueous-soluble and detergent-soluble retinal proteins in posterior uveitis, Arch. Ophthalmol., Apr. 2011, pp. 415-420, vol. 129. |
Kocak, N., et al., Intraocular lens haptic fracturing with the neodymium: YAG laser in vitro study, J. Cataract Refract. Surg., Apr. 2006, pp. 662-665, vol. 32. |
Kruusing, A. Underwater and water-assisted laser processing: Part 2—Etching, cutting and rarely used methods. Optics and Lasers in Engineering, 2004: pp. 329-352. |
“Lamellar Corneal Stromectomy for the Operative Treatment of Myopia” by Tadeusz Krwawicz, Notes, Cases, Instruments—1964, pp. 828-833. |
Lipid Deposits Posterior to Impermeable Intracorneal Lenses in Rhesus Monkeys: Clinical, Histochemical, and Ultrastructural Studies. Rodrigues et al. Refractive & Corneal Surgery, vol. 6, Jan./Feb. 1990: DO. 32-37. |
Lu Xuequan. Zhai Madlin, Li Jiuqiang, Ha Hongfei: “Radiation preparation and thermo-response swelling of interpenetrating polymer network hydrogel composed of PNIPAAm and PMMA” Radiation Physics and Chemistry, vol. 57, 2000, pp. 477-480, XP002473596. |
Mastel Precision: Fiber Optic Ring Illuminator (Product Nos. 3776 & 4050) U.S. Pat. No. 5,312,393, User Manual. Rev: A02: Jan. 11, 1995, pp. 1-25. |
Mastel Precision: The Ring Light. http://www.mastel.com/ring_light.html. Jul. 28, 2003. |
Measurement of the wave-front aberration of the eye by a fast psychophysical procedure. He et al. J. |
Opt. Soc. Am. A, vol. 15, No. 9: Sep. 1998, pp. 2449-2455. |
Microstructural Changes in Polyester Biotextiles During Implantation in Humans. King et al. NC. |
State University: JTATM, vol. 1, Issue 3, Spring 2001, pp. 1-8. |
Miller et al. “Quantification of the Pinhole effect” Perspectives in Refraction, vol. 21:347-350 1977. |
Moran, C., et al. Polyvinylidene flouride polymer applied in an intraocular pressure sensor, Jpn. J. Appl. Phys., 2005, pp. L885-L887, vol. 44, Issue 27. |
Near vision, lags of accommodation and myopia. Charman, W. N. Ophthal. Physiol. Opt., vol. 19, No. 2, pp. 126-133, 1999. |
New Visual Acuity Charts for Clinical Research. Ferris et al. American Journal of Ophthalmology, 94: 91-96, 1982. |
Night myopia and driving. Charman, W. N. Ophthal. Physiol. Opt., vol. 16, No. 6, p. 474-485, 1996. |
Notch in contrast sensitivity function of optical origin: diffraction effects of acrylic filters. Irving et al., Ophthal. Physiol. Opt., vol. 13, Apr. 1993: pp. 179-182. |
On modeling the causes of presbyopia. Glasser, A. Vision Research 41(2001) 3083-3087. |
On the linearity of accommodation dynamics. Charman, W. N. Vision Research 40 (2000) 2057-2066. |
Optical Aspects of Tolerances to Uncorrected Ocular Astigmatism. Charman et al. Optometry and Vision Science, vol. 70, No. 2: pp. 111-117, 1993. |
Optical Modeling of Contact Lens Performance Final Report Covering Period Jul. 15, 1994-Mar. 31, 1995. Grivenkamp et al. for Pilkington Barnes Hind, Issued Apr. 5, 1995. |
Optometric Clinical Practice Guideline Care of the Patient With Presbyopia: Reference Guide for Clinicians. Mancil et al. Mar. 20, 1998. |
Ozanics et al., “Prenatal Development of the Eye and its Adnexa,” Biomedical Foundation of Opthalmology, 1985, vol. 1, Chap 2, pp. 7-15. |
Patel, C.K., et al. “Imaging the macula through a black occlusive intraocular lens”. Arch. Ophthalmol. Oct. 2010; 128(10):1374-1376. |
PermaVision intracorneal lens shows promise for hyperopia. Kronemyer, Bob. Ocular Surgery News: Jan. 1, 2003; p. 8. |
Perspectives in Refraction: Quantification of the Pinhole Effect. Miller et al. Survey of Ophthalmology, vol. 21, No. 4, Jan./Feb. 1977, pp. 347-350. |
Peyman et al., “Modification of Rabbit Corneal Curvature with use of Carbon Dioxide Laser Burns,” Ophth, Surg., vol. 11, No. 5, 5/80, pp. 325-329. |
Puliafito, C., et al., “Excimer Laser Ablator of the Cornea & Lens,” Opthalmology, 6/85 vol. 92 No. 6, pp. 741-748. |
Sally Pobojewski, “New U-developed laser performs high-precision corneal surgery”, News and Information Services, The University Record, Jul. 16, 1997. |
Poly(methyl methacrylate) model study of optical surface quality after excimer laser photo refractive keratectomy. Hauge et al. J Cataract Refract Surg., vol. 27, Dec. 2001, pp. 2026-2035. |
Prince, S., et al., Sorption of alkylbenzyldimethylammonium chloride homologs to various filter media used in processing ophthalmics, APhA Annual Meeting, 1996, pp. 103, vol. 143. |
Procyon: Marketing Information for Distributors: Pupil Measurement and Refractive Surgery (Samples from Academic Papers 1994 and 2002). pp. 1-17. |
“Refractive Keratoplasty: Acute Morphologic Features,” by Baumgarter et al, The CLAO Journal—Apr. 1985, vol. II, No. 2, pp. 163-169. |
Refractive keratoplasty with intrastromal hydrogel lenticular implants. McCarey et al. Invest., Ophthalmol. Vis. ScL, Jul. 1981, pp. 107-115. |
Retinal Image Quality in the Human Eye as a Function of the Accommodation. Lopex-Gil et al. Vision. |
Research, vol. 38, No. 19,Jul. 3, 1998, pp. 1-11. |
Rosenbloom “The Controlled-Pupil Contact Lens in Low Vision Problems” Journal of the American Optometric Association, pp. 836, 838, 840 1969. |
Sato, “A New Surgical Approach to Myopia”, Am. J. Ophthalmol. 36:823, 1953. |
Shingleton, B., Reply: pupil stretch technique, J. Cataract Refract. Surg., 2007, pp. 362, vol. 33. |
Simple parametric model of the human ocular modulation transfer function, A. Deeley et al. Ophthal. |
Physiol. Opt., vol. 11, Jan. 1991, pp. 91-93. |
Karin R. Slettin, MD et al., “An In Vivo Model of Femtosecond Laser Intrastromal Refractive Surgery”, Experimental Science, Ophthalmic Surgery and Lasers, Nov./Dec. 1999, vol. 30, No. 9, pp. 742-749. |
Subjective Depth-of-Focus of the Eye. Atchison et al. Optometry and Vision Science, vol. 74, No. 7, Jul. 1997, pp. 511-520. |
Subjective Sensitivity to Small Changes in the Contrast of a Suprathreshold Grating, The. Walsh et al. Vision Res., vol. 30, No. 1, pp. 163-193, 1990. |
Surface Modification Properties of Parylene for Medical Applications, The. Wolgemuth, Lonny.Business Briefing: Medical Device Manfacturing & Technology 2002, pp. 1-4. |
Surface tension control of collagen biomaterials by the selective hydrolysis of internal carboxyamides of the protein matrix. Revista Brasileira de Engenharia Biomedica, v. 15, n. 1-2, p. 55-61, Jan./Ago. 1999. |
Surgeon: Severe corneal lesions after Lasik are not stage 4 DLK. Piechocki, Michael. Ocular SurgeryNews; Jan. 1, 2003, pp. 16-17. |
Subrayan, V., et al., Improving quality of vision with an anterior surface modified prolate intraocular lens: A prosepective clinical trial, Int. J. Ophthalmol., Aug. 2007, pp. 918-920, vol. 7, No. 4. |
Swinger et al., “Keratophakia and Keratomileusis—Clinical Results”, American Academy of Ophthalmology, Aug. 1981, vol. 88, No. 8, pp. 709-715. |
Taboda, J., et al., “Response of the Corneal Epithelium to K.F. Excimer Laser Pulses,” Health Physics, 1981, vol. 40, pp. 677-683. |
Takahashi, E. “Use and Interpretation of the Pinhole Test” The Optometric Weekly, pp. 83-86 1965. |
Tasaki, I., et al., Demonstration of heat production associated with spreading depression in the amphibian retina, Biochem. Biophys. Res. Commun., 1991, pp. 293-297, vol. 174. |
Theoretical and practical performance of a concentric bifocal intraocular implant lens. Charman, W.N. Vision Research 38 (1998) 2841-2853. |
Trokel, S., et al., “Excimer Laser Surgery of the Cornea,” Am. J. Opthalmology, 1983 vol. 96, pp. 710-715. |
Use of a digital infrared pupillometer to assess patient suitability for refractive surgery. Rosen et al. J Cataract Refract Surg., vol. 28: Aug. 2002. pp. 1433-1438. |
Vision and driving—a literature review and commentary. Charman, W.N. Ophthal. Physiol. Opt., vol. 17, No. 5, pp. 371-391, 1997. |
Wesley, N. K. “Research on the Multi-Range Lens,” pp. 18-24, 1970. |
Yamauchi et al., “Cultivation of fibroblast cells on keratin coated substrata”, Polymers for Tissue Engineering, pp. 329-340, VS 1998. |
Yusuf, et al., “Inability to perform posterior segment monitoring by scanning laser ophthalmoscopy or optical coherence tomography with some occlusive intraocular lenses in clinical use”, J. Cataract Refract. Surg., Mar. 2012, 38: 513-513. |
Yusuf, et al., “Occlusive IDLs for Intractable Diplopia Demonstrate a Novel Near-Infrared Window of Transmission for SLO/OCT Imaging and Clinical Assessment”. Investigative Ophthalmology & Visual Science, May 2011, 52(6): 3737-3743. |
Zavala et al., “Refractive Keratoplosty: Lathing and Cyropreservation,” CLAO Journal, Apr. 1985, 11:155-162. |
Number | Date | Country | |
---|---|---|---|
20210244532 A1 | Aug 2021 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13802340 | Mar 2013 | US |
Child | 14961308 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16511437 | Jul 2019 | US |
Child | 17249045 | US | |
Parent | 15436150 | Feb 2017 | US |
Child | 16511437 | US | |
Parent | 14961308 | Dec 2015 | US |
Child | 15436150 | US |